

# Efficacy of a Tetravalent Dengue Vaccine in Children in

New England Journal of Medicine

372, 113-123

DOI: [10.1056/nejmoa1411037](https://doi.org/10.1056/nejmoa1411037)

Citation Report

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 1  | Technologies for making new vaccines. , 2013, , 1182-1199.   |     | 3         |
| 2  | Protection against dengue disease by synthetic nucleic acid antibody prophylaxis/immunotherapy. Scientific Reports, 2015, 5, 12616.  | 1.6 | 65        |
| 3  | Exploration of unsupervised feature selection methods in relation to the prediction of cytokine release effect correlated to antibody features in RV144 vaccines. , 2015, , .                |     | 2         |
| 4  | Nieuwe vaccins. Bijblijven (Amsterdam, Netherlands), 2015, 31, 535-554.  | 0.0 | 0         |
| 6  | One More Shot for the Road: A Review and Update of Vaccinations for Pediatric International Travelers. Pediatric Annals, 2015, 44, e89-96.   | 0.3 | 3         |
| 7  | Immunogenic Subviral Particles Displaying Domain III of Dengue 2 Envelope Protein Vecteded by Measles Virus. Vaccines, 2015, 3, 503-518.   | 2.1 | 18        |
| 8  | Pichia pastoris-expressed dengue 3 envelope-based virus-like particles elicit predominantly domain III-focused high titer neutralizing antibodies. Frontiers in Microbiology, 2015, 6, 1005. | 1.5 | 33        |
| 10 | Tissue Barriers to Arbovirus Infection in Mosquitoes. Viruses, 2015, 7, 3741-3767.   | 1.5 | 347       |
| 11 | Dengue E Protein Domain III-Based DNA Immunisation Induces Strong Antibody Responses to All Four Viral Serotypes. PLoS Neglected Tropical Diseases, 2015, 9, e0003947.                       | 1.3 | 49        |
| 12 | Analysis of Dengue Virus Genetic Diversity during Human and Mosquito Infection Reveals Genetic Constraints. PLoS Neglected Tropical Diseases, 2015, 9, e0004044.                             | 1.3 | 47        |
| 13 | Proteasome Inhibition Suppresses Dengue Virus Egress in Antibody Dependent Infection. PLoS Neglected Tropical Diseases, 2015, 9, e0004058.   | 1.3 | 53        |
| 14 | Dengue Virus Infection of Aedes aegypti Requires a Putative Cysteine Rich Venom Protein. PLoS Pathogens, 2015, 11, e1005202.   | 2.1 | 49        |
| 15 | Epidemiological Scenario of Dengue in Brazil. BioMed Research International, 2015, 2015, 1-13.   | 0.9 | 87        |
| 16 | The global distribution of the arbovirus vectors Aedes aegypti and Ae. albopictus. ELife, 2015, 4, e08347.   | 2.8 | 1,428     |
| 17 | The dengue vaccine pipeline: Implications for the future of dengue control. Vaccine, 2015, 33, 3293-3298.  | 1.7 | 109       |
| 18 | The changing epidemiology of dengue in China, 1990-2014: a descriptive analysis of 25 years of nationwide surveillance data. BMC Medicine, 2015, 13, 100.                                    | 2.3 | 189       |
| 19 | Dengue Vaccines for Travelers: Has the Time Come?. Journal of Travel Medicine, 2015, 22, 200-202.  | 1.4 | 4         |
| 20 | Assessing the Economics of Dengue: Results from a Systematic Review of the Literature and Expert Survey. Pharmacoeconomics, 2015, 33, 1107-1135.   | 1.7 | 74        |

| #  | ARTICLE   | IF   | CITATIONS |
|----|---|------|-----------|
| 21 | Immunogenicity and safety of a tetravalent dengue vaccine during a five-year follow-up period. <i>Trials in Vaccinology</i> , 2015, 4, 19-23.   | 1.2  | 17        |
| 22 | Site-specific characterization of envelope protein N-glycosylation on Sanofi Pasteur's tetravalent CYD dengue vaccine. <i>Vaccine</i> , 2015, 33, 1360-1368.  | 1.7  | 16        |
| 23 | Influence of antibodies and T cells on dengue disease outcome: insights from interferon receptor-deficient mouse models. <i>Current Opinion in Virology</i> , 2015, 13, 61-66.  | 2.6  | 16        |
| 24 | Discovery of Dengue Virus NS4B Inhibitors. <i>Journal of Virology</i> , 2015, 89, 8233-8244.  | 1.5  | 77        |
| 25 | Influence of Fcγ3RIIIa-Expressing Cells on the Assessment of Neutralizing and Enhancing Serum Antibodies Elicited by a Live-Attenuated Tetravalent Dengue Vaccine. <i>Open Forum Infectious Diseases</i> , 2015, 2, ofv172. | 0.4  | 10        |
| 26 | First-in-human trial of a live-attenuated <i>Mycobacterium tuberculosis</i> vaccine. <i>Lancet Respiratory Medicine</i> , 2015, 3, 906-907.   | 5.2  | 1         |
| 27 | First Experience of Concomitant Vaccination Against Dengue and MMR in Toddlers. <i>Pediatric Infectious Disease Journal</i> , 2015, 34, 884-892.  | 1.1  | 13        |
| 28 | Tackling dengue fever: Current status and challenges. <i>Virology Journal</i> , 2015, 12, 212.  | 1.4  | 32        |
| 29 | Safety and Immunogenicity of a Dengue Virus Serotype-1 Purified-Inactivated Vaccine: Results of a Phase 1 Clinical Trial. <i>American Journal of Tropical Medicine and Hygiene</i> , 2015, 93, 454-460.                     | 0.6  | 40        |
| 30 | A new moment for facing dengue?. <i>Pathogens and Global Health</i> , 2015, 109, 2-3.   | 1.0  | 3         |
| 31 | Trial results raise hope for dengue fever vaccine. <i>BMJ</i> , The, 2015, 350, h141-h141.  | 3.0  | 0         |
| 32 | Modelling the immunological response to a tetravalent dengue vaccine from multiple phase-2 trials in Latin America and South East Asia. <i>Vaccine</i> , 2015, 33, 3746-3751.   | 1.7  | 34        |
| 33 | Protective Immune Responses to Dengue Virus Infection and Vaccines: Perspectives from the Field to the Bench. <i>Frontiers in Immunology</i> , 2015, 6, 75.   | 2.2  | 3         |
| 34 | Molecular Insight into Dengue Virus Pathogenesis and Its Implications for Disease Control. <i>Cell</i> , 2015, 162, 488-492.  | 13.5 | 219       |
| 35 | Burden of chikungunya in Latin American countries: estimates of disability-adjusted life-years (DALY) lost in the 2014 epidemic. <i>International Journal of Infectious Diseases</i> , 2015, 38, 60-61.                     | 1.5  | 35        |
| 36 | Challenge accepted: Human challenge trials for dengue. <i>Nature Medicine</i> , 2015, 21, 828-830.  | 15.2 | 7         |
| 37 | Efficacy and Long-Term Safety of a Dengue Vaccine in Regions of Endemic Disease. <i>New England Journal of Medicine</i> , 2015, 373, 1195-1206.   | 13.9 | 889       |
| 38 | A Candidate Dengue Vaccine Walks a Tightrope. <i>New England Journal of Medicine</i> , 2015, 373, 1263-1264.  | 13.9 | 43        |

| #  | ARTICLE   | IF   | CITATIONS |
|----|---|------|-----------|
| 39 | Preventing Dengue – Is the Possibility Now a Reality?. <i>New England Journal of Medicine</i> , 2015, 372, 172-173.   | 13.9 | 35        |
| 40 | Cryo-EM structure of an antibody that neutralizes dengue virus type 2 by locking E protein dimers. <i>Science</i> , 2015, 349, 88-91.   | 6.0  | 208       |
| 41 | The case for a typhoid vaccine probe study and overview of design elements. <i>Vaccine</i> , 2015, 33, C30-C35.   | 1.7  | 3         |
| 42 | CD8+ T Lymphocyte Expansion, Proliferation and Activation in Dengue Fever. <i>PLoS Neglected Tropical Diseases</i> , 2015, 9, e0003520.   | 1.3  | 22        |
| 43 | Trials and tribulations on the path to developing a dengue vaccine. <i>Vaccine</i> , 2015, 33, D24-D31.   | 1.7  | 30        |
| 44 | Preclinical development of a dengue tetravalent recombinant subunit vaccine: Immunogenicity and protective efficacy in nonhuman primates. <i>Vaccine</i> , 2015, 33, 4105-4116.               | 1.7  | 59        |
| 45 | Les tests de diagnostic rapide dans le diagnostic des arboviroses. <i>Revue Francophone Des Laboratoires</i> , 2015, 2015, 51-62.   | 0.0  | 1         |
| 46 | Structure-Guided Design of an Anti-dengue Antibody Directed to a Non-immunodominant Epitope. <i>Cell</i> , 2015, 162, 493-504.  | 13.5 | 111       |
| 47 | Reviewing Dengue: Still a Neglected Tropical Disease?. <i>PLoS Neglected Tropical Diseases</i> , 2015, 9, e0003632.   | 1.3  | 70        |
| 48 | Delivering vaccines to the people who need them most. <i>Philosophical Transactions of the Royal Society B: Biological Sciences</i> , 2015, 370, 20140150.                                    | 1.8  | 9         |
| 49 | Estimating Dengue Transmission Intensity from Sero-Prevalence Surveys in Multiple Countries. <i>PLoS Neglected Tropical Diseases</i> , 2015, 9, e0003719.                                     | 1.3  | 84        |
| 50 | CRL2 aids elimination of truncated selenoproteins produced by failed UGA/Sec decoding. <i>Science</i> , 2015, 349, 91-95.   | 6.0  | 56        |
| 51 | Machine Learning Methods Enable Predictive Modeling of Antibody Feature:Function Relationships in RV144 Vaccines. <i>PLoS Computational Biology</i> , 2015, 11, e1004185.                     | 1.5  | 50        |
| 53 | Differential efficacy of dengue vaccine by immune status. <i>Lancet, The</i> , 2015, 385, 1726.   | 6.3  | 13        |
| 54 | Dengue vaccine – time to act now. <i>Lancet, The</i> , 2015, 385, 1725-1726.  | 6.3  | 1         |
| 55 | Polymorphisms in the retinoic acid-1 like-receptor family of genes and their association with clinical outcome of dengue virus infection. <i>Archives of Virology</i> , 2015, 160, 1555-1560. | 0.9  | 6         |
| 56 | Dengue: what it is and why there is more. <i>Science Bulletin</i> , 2015, 60, 661-664.  | 4.3  | 5         |
| 57 | Current Neurological Observations and Complications of Dengue Virus Infection. <i>Current Neurology and Neuroscience Reports</i> , 2015, 15, 29.  | 2.0  | 26        |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 58 | Tetravalent dengue vaccine for children. <i>Indian Pediatrics</i> , 2015, 52, 237-240.   | 0.2 | 0         |
| 59 | CD8 <sup>+</sup> T Cells Can Mediate Short-Term Protection against Heterotypic Dengue Virus Reinfection in Mice. <i>Journal of Virology</i> , 2015, 89, 6494-6505.   | 1.5 | 78        |
| 60 | Complexity of Neutralizing Antibodies against Multiple Dengue Virus Serotypes after Heterotypic Immunization and Secondary Infection Revealed by In-Depth Analysis of Cross-Reactive Antibodies. <i>Journal of Virology</i> , 2015, 89, 7348-7362. | 1.5 | 55        |
| 61 | Human CD8 <sup>+</sup> T-Cell Responses Against the 4 Dengue Virus Serotypes Are Associated With Distinct Patterns of Protein Targets. <i>Journal of Infectious Diseases</i> , 2015, 212, 1743-1751.   | 1.9 | 129       |
| 62 | Dengue in Latin America: A Persistent and Growing Public Health Challenge. <i>Neglected Tropical Diseases</i> , 2015, , 203-224.   | 0.4 | 7         |
| 63 | A Promising, Single-Dose, Live Attenuated Tetravalent Dengue Vaccine Candidate. <i>Journal of Infectious Diseases</i> , 2015, 212, 681-683.  | 1.9 | 6         |
| 64 | Dengue Virus Infection with Highly Neutralizing Levels of Cross-Reactive Antibodies Causes Acute Lethal Small Intestinal Pathology without a High Level of Viremia in Mice. <i>Journal of Virology</i> , 2015, 89, 5847-5861.                      | 1.5 | 69        |
| 65 | Safety and Immunogenicity of a Live Attenuated Tetravalent Dengue Vaccine Candidate in Flavivirus-Naive Adults: A Randomized, Double-Blinded Phase 1 Clinical Trial. <i>Journal of Infectious Diseases</i> , 2015, 212, 1032-1041.                 | 1.9 | 79        |
| 66 | Current status and future prospects of yellow fever vaccines. <i>Expert Review of Vaccines</i> , 2015, 14, 1479-1492.  | 2.0 | 59        |
| 67 | Generation and preclinical immunogenicity study of dengue type 2 virus-like particles derived from stably transfected mosquito cells. <i>Vaccine</i> , 2015, 33, 5613-5622.  | 1.7 | 25        |
| 69 | Historical inability to control <i>Aedes aegypti</i> as a main contributor of fast dispersal of chikungunya outbreaks in Latin America. <i>Antiviral Research</i> , 2015, 124, 30-42.  | 1.9 | 57        |
| 71 | Dengue vaccines at a crossroad. <i>Science</i> , 2015, 350, 626-627.   | 6.0 | 28        |
| 72 | Expression of enhancing-activity-free neutralizing antibody against dengue type 1 virus in plasmid-inoculated mice. <i>Vaccine</i> , 2015, 33, 6070-6077.  | 1.7 | 2         |
| 73 | Defining New Therapeutics Using a More Immunocompetent Mouse Model of Antibody-Enhanced Dengue Virus Infection. <i>MBio</i> , 2015, 6, e01316-15.  | 1.8 | 40        |
| 74 | A New Quaternary Structure Epitope on Dengue Virus Serotype 2 Is the Target of Durable Type-Specific Neutralizing Antibodies. <i>MBio</i> , 2015, 6, e01461-15.  | 1.8 | 89        |
| 75 | Next generation dengue vaccines: A review of the preclinical development pipeline. <i>Vaccine</i> , 2015, 33, 7091-7099.   | 1.7 | 44        |
| 76 | Analysis of cell-mediated immune responses in support of dengue vaccine development efforts. <i>Vaccine</i> , 2015, 33, 7083-7090.   | 1.7 | 10        |
| 78 | Advances in genetically modified <i>Aedes aegypti</i> to control transmission of dengue viruses. <i>Future Virology</i> , 2015, 10, 609-624.   | 0.9 | 6         |

| #  | ARTICLE  | IF   | CITATIONS |
|----|--|------|-----------|
| 79 | Animal models for studying dengue pathogenesis and therapy. <i>Antiviral Research</i> , 2015, 123, 5-14.   | 1.9  | 84        |
| 80 | Lot-to-lot consistency of a tetravalent dengue vaccine in healthy adults in Australia: A randomised study. <i>Vaccine</i> , 2015, 33, 5127-5134.                           | 1.7  | 21        |
| 81 | Australasian Society for Infectious Diseases 2015 conference report: one health, one world. <i>Future Virology</i> , 2015, 10, 667-670.                                    | 0.9  | 0         |
| 82 | Deep Recombination: RNA and ssDNA Virus Genes in DNA Virus and Host Genomes. <i>Annual Review of Virology</i> , 2015, 2, 203-217.  | 3.0  | 38        |
| 83 | Dengue fever. <i>BMJ, The</i> , 2015, 351, h4661.  | 3.0  | 108       |
| 84 | Anti-infective vaccination in the 21st centuryâ€”new horizons for personal and public health. <i>Current Opinion in Microbiology</i> , 2015, 27, 96-102.                   | 2.3  | 13        |
| 85 | Dengue: an update on treatment options. <i>Future Microbiology</i> , 2015, 10, 2017-2031.  | 1.0  | 31        |
| 86 | Trials and Tribulations on the Path to Developing a Dengue Vaccine. <i>American Journal of Preventive Medicine</i> , 2015, 49, S334-S344.                                  | 1.6  | 34        |
| 87 | Development of a recombinant, chimeric tetravalent dengue vaccine candidate. <i>Vaccine</i> , 2015, 33, 7112-7120.   | 1.7  | 37        |
| 88 | The Potential Impact of Vaccination on the Dynamics of Dengue Infections. <i>Bulletin of Mathematical Biology</i> , 2015, 77, 2212-2230.                                   | 0.9  | 16        |
| 89 | New insights into the immunopathology and control of dengue virus infection. <i>Nature Reviews Immunology</i> , 2015, 15, 745-759.   | 10.6 | 282       |
| 90 | Dengue in children: a systematic review of clinical and laboratory factors associated with severity. <i>Expert Review of Anti-Infective Therapy</i> , 2015, 13, 1441-1456. | 2.0  | 16        |
| 91 | Genotypic Differences in Dengue Virus Neutralization Are Explained by a Single Amino Acid Mutation That Modulates Virus Breathing. <i>MBio</i> , 2015, 6, e01559-15.       | 1.8  | 71        |
| 92 | Development of the Sanofi Pasteur tetravalent dengue vaccine: One more step forward. <i>Vaccine</i> , 2015, 33, 7100-7111.   | 1.7  | 126       |
| 93 | Arboviruses. , 0, , 493-514.   |      | 1         |
| 94 | Cell Biology of Virus Infection. The Role of Cytoskeletal Dynamics Integrity in the Effectiveness of Dengue Virus Infection. , 2016, , .                                   |      | 3         |
| 95 | La virologÃa, mÃ¡s necesaria que nunca. <i>Biomedica</i> , 2016, 36, 5.  | 0.3  | 0         |
| 96 | Zika antiviral chemotherapy: identification of drugs and promising starting points for drug discovery from an FDA-approved library. <i>F1000Research</i> , 2016, 5, 2523.  | 0.8  | 60        |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 97  | Prospects for dengue vaccines for travelers. <i>Clinical and Experimental Vaccine Research</i> , 2016, 5, 89.  | 1.1 | 9         |
| 98  | Evaluating the impact of a tetravalent vaccine in populations with high-incidence of Dengue: a mathematical model. <i>Nonlinear Analysis and Differential Equations</i> , 2016, 4, 133-142.  | 0.1 | 0         |
| 99  | Safety Overview of a Recombinant Live-Attenuated Tetravalent Dengue Vaccine: Pooled Analysis of Data from 18 Clinical Trials. <i>PLoS Neglected Tropical Diseases</i> , 2016, 10, e0004821.  | 1.3 | 38        |
| 101 | Zika Virus: Prospects for the Development of Vaccine and Antiviral Agents. , 2016, 08, .   |     | 6         |
| 102 | Economic Analysis of Genetically Modified Mosquito Strategies. , 2016, , 375-408.  |     | 5         |
| 103 | Dengue Fever: Causes, Complications, and Vaccine Strategies. <i>Journal of Immunology Research</i> , 2016, 2016, 1-14.   | 0.9 | 171       |
| 104 | The Impact of Vaccination on the Epidemiology of Infectious Diseases. , 2016, , 3-31.  |     | 12        |
| 105 | Immunological Correlates of Vaccine-Mediated Protection. , 2016, , 121-149.  |     | 0         |
| 106 | Cytotoxic CD4 T Cells: Differentiation, Function, and Application to Dengue Virus Infection. <i>Frontiers in Immunology</i> , 2016, 7, 531.  | 2.2 | 74        |
| 107 | Dengue vaccine: local decisions, global consequences. <i>Bulletin of the World Health Organization</i> , 2016, 94, 850-855.  | 1.5 | 15        |
| 108 | The Long-Term Safety, Public Health Impact, and Cost-Effectiveness of Routine Vaccination with a Recombinant, Live-Attenuated Dengue Vaccine (Dengvaxia): A Model Comparison Study. <i>PLoS Medicine</i> , 2016, 13, e1002181.           | 3.9 | 178       |
| 109 | Cytokine Profile of Children Hospitalized with Virologically-Confirmed Dengue during Two Phase III Vaccine Efficacy Trials. <i>PLoS Neglected Tropical Diseases</i> , 2016, 10, e0004830.  | 1.3 | 18        |
| 110 | Extended Evaluation of Virological, Immunological and Pharmacokinetic Endpoints of CELADEN: A Randomized, Placebo-Controlled Trial of Celgosivir in Dengue Fever Patients. <i>PLoS Neglected Tropical Diseases</i> , 2016, 10, e0004851. | 1.3 | 53        |
| 111 | Public Health Responses to and Challenges for the Control of Dengue Transmission in High-Income Countries: Four Case Studies. <i>PLoS Neglected Tropical Diseases</i> , 2016, 10, e0004943.  | 1.3 | 29        |
| 112 | Synthetic B-Cell Epitopes Eliciting Cross-Neutralizing Antibodies: Strategies for Future Dengue Vaccine. <i>PLoS ONE</i> , 2016, 11, e0155900.   | 1.1 | 22        |
| 113 | Knowledge and practices related to dengue and its vector: a community-based study from Southeast Brazil. <i>Revista Da Sociedade Brasileira De Medicina Tropical</i> , 2016, 49, 222-226.  | 0.4 | 21        |
| 114 | Recent advances in understanding dengue. <i>F1000Research</i> , 2016, 5, 78.   | 0.8 | 40        |
| 115 | Serotype influences on dengue severity: a cross-sectional study on 485 confirmed dengue cases in VitÃ³ria, Brazil. <i>BMC Infectious Diseases</i> , 2016, 16, 320.   | 1.3 | 75        |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 116 | Vascular leakage in dengue – clinical spectrum and influence of parenteral fluid therapy. <i>Tropical Medicine and International Health</i> , 2016, 21, 445-453.   | 1.0 | 18        |
| 117 | Licensed Dengue Vaccine: Public Health Conundrum and Scientific Challenge. <i>American Journal of Tropical Medicine and Hygiene</i> , 2016, 95, 741-745.   | 0.6 | 39        |
| 118 | Immunogenicity and Safety of Yellow Fever Vaccine (Stamaril) When Administered Concomitantly With a Tetravalent Dengue Vaccine Candidate in Healthy Toddlers at 12–13 Months of Age in Colombia and Peru. <i>Pediatric Infectious Disease Journal</i> , 2016, 35, 1140-1147. | 1.1 | 24        |
| 119 | Neglected Tropical Diseases - Oceania. <i>Neglected Tropical Diseases</i> , 2016, , .  | 0.4 | 2         |
| 120 | Infectious dengue vesicles derived from CD61+ cells in acute patient plasma exhibited a diaphanous appearance. <i>Scientific Reports</i> , 2016, 5, 17990.   | 1.6 | 18        |
| 121 | Predicting Overall Vaccine Efficacy in a New Setting by Re-calibrating Baseline Covariate and Intermediate Response Endpoint Effect Modifiers of Type-Specific Vaccine Efficacy. <i>Epidemiologic Methods</i> , 2016, 5, 93-112.   | 0.8 | 13        |
| 122 | Once and future epidemics: Zika virus emerging. <i>Science Translational Medicine</i> , 2016, 8, 330ed2.   | 5.8 | 5         |
| 123 | Characterizing the Conformational Landscape of Flavivirus Fusion Peptides via Simulation and Experiment. <i>Scientific Reports</i> , 2016, 6, 19160.   | 1.6 | 17        |
| 124 | Dissecting antibodies induced by a chimeric yellow fever-dengue, live-attenuated, tetravalent dengue vaccine (CYD-TDV) in naïve and dengue exposed individuals. <i>Journal of Infectious Diseases</i> , 2017, 215, jiw576.   | 1.9 | 97        |
| 125 | Dengue: Emergence, Determinants and Climate Change. <i>Neglected Tropical Diseases</i> , 2016, , 237-248.  | 0.4 | 1         |
| 126 | Dengue fever: The monsoon menace. <i>Indian Journal of Medical Specialities</i> , 2016, 7, 139-141.  | 0.1 | 0         |
| 127 | Immunogenicity of a novel tetravalent vaccine formulation with four recombinant lipidated dengue envelope protein domain IIIs in mice. <i>Scientific Reports</i> , 2016, 6, 30648.   | 1.6 | 32        |
| 128 | Production of a Recombinant Dengue Virus 2 NS5 Protein and Potential Use as a Vaccine Antigen. <i>Vaccine Journal</i> , 2016, 23, 460-469.   | 3.2 | 25        |
| 129 | Pyrethroid resistance in <i>Aedes aegypti</i> and <i>Aedes albopictus</i> : Important mosquito vectors of human diseases. <i>Pesticide Biochemistry and Physiology</i> , 2016, 133, 1-12.  | 1.6 | 265       |
| 130 | Estimating the public health importance of the CYD-tetravalent dengue vaccine: Vaccine preventable disease incidence and numbers needed to vaccinate. <i>Vaccine</i> , 2016, 34, 2397-2401.  | 1.7 | 18        |
| 131 | Evaluation of protection induced by a dengue virus serotype 2 envelope domain III protein scaffold/DNA vaccine in non-human primates. <i>Vaccine</i> , 2016, 34, 3500-3507.  | 1.7 | 26        |
| 132 | Development of a monoclonal antibody specific to envelope domain III with broad-spectrum detection of all four dengue virus serotypes. <i>Biochemical and Biophysical Research Communications</i> , 2016, 473, 894-898.  | 1.0 | 3         |
| 133 | Introducing dengue vaccine: Implications for diagnosis in dengue vaccinated subjects. <i>Vaccine</i> , 2016, 34, 2759-2761.  | 1.7 | 9         |



| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 134 | Effects of Larval Nutrition on <i>Wolbachia</i> -Based Dengue Virus Interference in <i>Aedes aegypti</i> (Diptera: Culicidae). <i>Journal of Medical Entomology</i> , 2016, 53, 894-901.  | 0.9 | 12        |
| 135 | Production of dengue virus envelope protein domain III-based antigens in tobacco chloroplasts using inducible and constitutive expression systems. <i>Plant Molecular Biology</i> , 2016, 91, 497-512.                                | 2.0 | 33        |
| 136 | Dengue Virus Immunopathogenesis: Lessons Applicable to the Emergence of Zika Virus. <i>Journal of Molecular Biology</i> , 2016, 428, 3429-3448.   | 2.0 | 33        |
| 137 | A humanized monoclonal antibody neutralizes yellow fever virus strain 17D-204 <i>in vitro</i> but does not protect a mouse model from disease. <i>Antiviral Research</i> , 2016, 131, 92-99.  | 1.9 | 8         |
| 138 | Cellufine sulfate column chromatography as a simple, rapid, and effective method to purify dengue virus. <i>Journal of Virological Methods</i> , 2016, 234, 174-177.  | 1.0 | 8         |
| 139 | Genomic characterization and phylogenetic analysis of Zika virus circulating in the Americas. <i>Infection, Genetics and Evolution</i> , 2016, 43, 43-49.   | 1.0 | 103       |
| 140 | The first licensed dengue vaccine: an important tool for integrated preventive strategies against dengue virus infection. <i>Expert Review of Vaccines</i> , 2016, 15, 795-798.   | 2.0 | 30        |
| 141 | Oral immunisation of mice with transgenic rice calli expressing cholera toxin B subunit fused to consensus dengue cEDIII antigen induces antibodies to all four dengue serotypes. <i>Plant Molecular Biology</i> , 2016, 92, 347-356. | 2.0 | 16        |
| 142 | Immunization with electroporation enhances the protective effect of a DNA vaccine candidate expressing prME antigen against dengue virus serotype 2 infection. <i>Clinical Immunology</i> , 2016, 171, 41-49.                         | 1.4 | 16        |
| 143 | Tetravalent Dengue Vaccine Reduces Symptomatic and Asymptomatic Dengue Virus Infections in Healthy Children and Adolescents Aged 2-16 Years in Asia and Latin America. <i>Journal of Infectious Diseases</i> , 2016, 214, 994-1000.   | 1.9 | 41        |
| 144 | Neurotropic Viral Infections. , 2016, , .   |     | 3         |
| 145 | Flavivirus RNA transactions from viral entry to genome replication. <i>Antiviral Research</i> , 2016, 134, 244-249.   | 1.9 | 65        |
| 146 | A Tetravalent Formulation Based on Recombinant Nucleocapsid-like Particles from Dengue Viruses Induces a Functional Immune Response in Mice and Monkeys. <i>Journal of Immunology</i> , 2016, 197, 3597-3606.                         | 0.4 | 25        |
| 147 | Critique of World Health Organization Recommendation of a Dengue Vaccine. <i>Journal of Infectious Diseases</i> , 2016, 214, 1793-1795.   | 1.9 | 52        |
| 148 | Population Perspectives and World Health Organization Recommendations for CYD-TDV Dengue Vaccine. <i>Journal of Infectious Diseases</i> , 2016, 214, 1796-1799.   | 1.9 | 55        |
| 149 | Tetravalent Dengue Vaccine: A Review in the Prevention of Dengue Disease. <i>Drugs</i> , 2016, 76, 1301-1312.   | 4.9 | 52        |
| 150 | Dengue serotype immune-interactions and their consequences for vaccine impact predictions. <i>Epidemics</i> , 2016, 16, 40-48.  | 1.5 | 29        |
| 151 | Vaccines and immunization strategies for dengue prevention. <i>Emerging Microbes and Infections</i> , 2016, 5, 1-6.   | 3.0 | 50        |

| #   | ARTICLE   | IF   | CITATIONS |
|-----|---|------|-----------|
| 152 | SAGE committee advice on dengue vaccine. Lancet Infectious Diseases, The, 2016, 16, 880-882.  | 4.6  | 18        |
| 153 | Unique safety issues associated with virus-vectored vaccines: Potential for and theoretical consequences of recombination with wild type virus strains. Vaccine, 2016, 34, 6610-6616.                   | 1.7  | 32        |
| 154 | Benefits and risks of the Sanofi-Pasteur dengue vaccine: Modeling optimal deployment. Science, 2016, 353, 1033-1036.  | 6.0  | 195       |
| 155 | New Vaccines on the Horizon. Current Pediatrics Reports, 2016, 4, 74-83.  | 1.7  | 0         |
| 156 | Immunization in patients with inflammatory rheumatic diseases. Best Practice and Research in Clinical Rheumatology, 2016, 30, 946-963.  | 1.4  | 13        |
| 157 | Complement-independent dengue virus type 1 infection-enhancing antibody reduces complement-dependent and -independent neutralizing antibody activity. Vaccine, 2016, 34, 6449-6457.                     | 1.7  | 8         |
| 158 | A Tetravalent Sub-unit Dengue Vaccine Formulated with Ionizable Cationic Lipid Nanoparticle induces Significant Immune Responses in Rodents and Non-Human Primates. Scientific Reports, 2016, 6, 34215. | 1.6  | 51        |
| 159 | Neurotropic Dengue Virus Infections. , 2016, , 259-272.   |      | 1         |
| 160 | The risks behind Dengvaxia recommendation. Lancet Infectious Diseases, The, 2016, 16, 882-883.  | 4.6  | 92        |
| 161 | Vaccines against chikungunya, Zika and other emerging Aedes mosquito-borne viruses: unblocking existing bottlenecks. Future Virology, 2016, 11, 723-730.  | 0.9  | 2         |
| 162 | Human antibody response to dengue virus: implications for dengue vaccine design. Tropical Medicine and Health, 2016, 44, 1.   | 1.0  | 36        |
| 163 | The economic promise of developing and implementing dengue vaccines: Evidence from a systematic review. Vaccine, 2016, 34, 6133-6147.   | 1.7  | 6         |
| 164 | A MVA construct expressing a secretable form of the Dengue virus 3 envelope protein protects immunized mice from dengue-induced encephalitis. Vaccine, 2016, 34, 6120-6122.                             | 1.7  | 4         |
| 165 | Cross-reactive antibodies enhance live attenuated virus infection for increased immunogenicity. Nature Microbiology, 2016, 1, 16164.  | 5.9  | 75        |
| 166 | Dengue infection. Nature Reviews Disease Primers, 2016, 2, 16055.   | 18.1 | 415       |
| 167 | Comparison of two detailed models of <i>Aedes aegypti</i> population dynamics. Ecosphere, 2016, 7, e01515.  | 1.0  | 22        |
| 168 | The live attenuated dengue vaccine TV003 elicits complete protection against dengue in a human challenge model. Science Translational Medicine, 2016, 8, 330ra36.                                       | 5.8  | 227       |
| 169 | Seroepidemiology of Asymptomatic Dengue Virus Infection in Jeddah, Saudi Arabia. Virology: Research and Treatment, 2016, 7, VRT.S34187.   | 3.5  | 27        |

| #   | ARTICLE  | IF   | CITATIONS |
|-----|--|------|-----------|
| 170 | Virus-like particles derived from <i>Pichia pastoris</i> -expressed dengue virus type 1 glycoprotein elicit homotypic virus-neutralizing envelope domain III-directed antibodies. <i>BMC Biotechnology</i> , 2016, 16, 50. | 1.7  | 26        |
| 171 | The currently best estimate for worldwide dengue vaccine efficacy. <i>AIP Conference Proceedings</i> , 2016, , .   | 0.3  | 3         |
| 172 | Polyandry Depends on Postmating Time Interval in the Dengue Vector <i>Aedes aegypti</i> . <i>American Journal of Tropical Medicine and Hygiene</i> , 2016, 94, 780-785.  | 0.6  | 56        |
| 173 | Viral vectors as vaccine platforms: from immunogenicity to impact. <i>Current Opinion in Immunology</i> , 2016, 41, 47-54.   | 2.4  | 137       |
| 174 | A novel mosquito ubiquitin targets viral envelope protein for degradation and reduces virion production during dengue virus infection. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 2016, 1860, 1898-1909.    | 1.1  | 36        |
| 175 | <sup>1</sup> H Nuclear Magnetic Resonance Metabolomics of Plasma Unveils Liver Dysfunction in Dengue Patients. <i>Journal of Virology</i> , 2016, 90, 7429-7443.   | 1.5  | 28        |
| 176 | Investigational drugs in early development for treating dengue infection. <i>Expert Opinion on Investigational Drugs</i> , 2016, 25, 1059-1069.  | 1.9  | 18        |
| 177 | Backward bifurcation and control in transmission dynamics of arboviral diseases. <i>Mathematical Biosciences</i> , 2016, 278, 100-129.   | 0.9  | 28        |
| 178 | Dengue vaccines: Are they safe for travelers?. <i>Travel Medicine and Infectious Disease</i> , 2016, 14, 378-383.  | 1.5  | 17        |
| 179 | Clinical development update: 1st dengue vaccine candidate. <i>Asian Journal of Pharmaceutical Sciences</i> , 2016, 11, 20-21.  | 4.3  | 0         |
| 180 | Response to Orellano et al. regarding cost-utility analysis of dengue vaccination in a country with heterogeneous risk of dengue transmission. <i>Vaccine</i> , 2016, 34, 3222.  | 1.7  | 0         |
| 181 | Reaction mechanism of the dengue virus serine protease: a QM/MM study. <i>Physical Chemistry Chemical Physics</i> , 2016, 18, 30288-30296.   | 1.3  | 12        |
| 182 | Novel concept on antiviral strategies to dengue. <i>Current Opinion in Virology</i> , 2016, 18, 97-108.  | 2.6  | 6         |
| 183 | Biotechnological value of <i>Moringa oleifera</i> seed cake as source of insecticidal lectin against <i>Aedes aegypti</i> . <i>Process Biochemistry</i> , 2016, 51, 1683-1690.   | 1.8  | 22        |
| 184 | A Dengue Vaccine. <i>Cell</i> , 2016, 166, 1.  | 13.5 | 98        |
| 185 | Age specific differences in efficacy and safety for the CYD-tetravalent dengue vaccine. <i>Expert Review of Vaccines</i> , 2016, 15, 437-441.  | 2.0  | 17        |
| 186 | Cost-utility analysis of dengue vaccination in a country with heterogeneous risk of dengue transmission. <i>Vaccine</i> , 2016, 34, 616-621.   | 1.7  | 20        |
| 187 | Recombinant lipidated dengue-3 envelope protein domain III stimulates broad immune responses in mice. <i>Vaccine</i> , 2016, 34, 1054-1061.  | 1.7  | 19        |

| #   | ARTICLE   | IF   | CITATIONS |
|-----|---|------|-----------|
| 188 | The development of therapeutic antibodies against dengue virus. <i>Antiviral Research</i> , 2016, 128, 7-19.  | 1.9  | 50        |
| 189 | Current issues in the economics of vaccination against dengue. <i>Expert Review of Vaccines</i> , 2016, 15, 519-528.  | 2.0  | 11        |
| 190 | Development of TV003/TV005, a single dose, highly immunogenic live attenuated dengue vaccine; what makes this vaccine different from the Sanofi-Pasteur CYD $\Delta$ , $\epsilon$ vaccine?. <i>Expert Review of Vaccines</i> , 2016, 15, 509-517. | 2.0  | 119       |
| 191 | Immune correlates for dengue vaccine development. <i>Expert Review of Vaccines</i> , 2016, 15, 455-465.   | 2.0  | 22        |
| 192 | Estimation of parameters related to vaccine efficacy and dengue transmission from two large phase III studies. <i>Vaccine</i> , 2016, 34, 6417-6425.  | 1.7  | 42        |
| 193 | Dengue vaccine: hypotheses to understand CYD-TDV-induced protection. <i>Nature Reviews Microbiology</i> , 2016, 14, 45-54.  | 13.6 | 151       |
| 194 | A recombinant, chimeric tetravalent dengue vaccine candidate based on a dengue virus serotype 2 backbone. <i>Expert Review of Vaccines</i> , 2016, 15, 497-508.   | 2.0  | 70        |
| 195 | A phosphomimetic-based mechanism of dengue virus to antagonize innate immunity. <i>Nature Immunology</i> , 2016, 17, 523-530.   | 7.0  | 90        |
| 196 | Status of vaccine research and development of vaccines for dengue. <i>Vaccine</i> , 2016, 34, 2934-2938.  | 1.7  | 97        |
| 197 | A novel dengue virus serotype 1 vaccine candidate based on Japanese encephalitis virus vaccine strain SA14-14-2 as the backbone. <i>Archives of Virology</i> , 2016, 161, 1517-1526.  | 0.9  | 6         |
| 198 | Current perspectives on dengue episode in Malaysia. <i>Asian Pacific Journal of Tropical Medicine</i> , 2016, 9, 395-401.   | 0.4  | 29        |
| 199 | Symptomatic Dengue in Children in 10 Asian and Latin American Countries. <i>New England Journal of Medicine</i> , 2016, 374, 1155-1166.   | 13.9 | 117       |
| 200 | International Dengue Vaccine Communication and Advocacy: Challenges and Way Forward. <i>Expert Review of Vaccines</i> , 2016, 15, 539-545.  | 2.0  | 6         |
| 201 | Low antibody titers 5 years after vaccination with the CYD-TDV dengue vaccine in both pre-immune and naïve vaccinees. <i>Human Vaccines and Immunotherapeutics</i> , 2016, 12, 1265-1273.   | 1.4  | 20        |
| 202 | Infectious Diseases and Rural Livelihood in Developing Countries. , 2016, , .   |      | 18        |
| 203 | The global burden of dengue: an analysis from the Global Burden of Disease Study 2013. <i>Lancet Infectious Diseases</i> , The, 2016, 16, 712-723.  | 4.6  | 770       |
| 204 | Protective and immunological behavior of chimeric yellow fever dengue vaccine. <i>Vaccine</i> , 2016, 34, 1643-1647.  | 1.7  | 143       |
| 205 | A comparative study on active and passive epidemiological surveillance for dengue in five countries of Latin America. <i>International Journal of Infectious Diseases</i> , 2016, 44, 44-49.  | 1.5  | 58        |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 206 | Functional Transplant of a Dengue Virus Serotype 3 (DENV3)-Specific Human Monoclonal Antibody Epitope into DENV1. <i>Journal of Virology</i> , 2016, 90, 5090-5097.   | 1.5 | 30        |
| 207 | Human challenge trials in vaccine development: Strasbourg, September 29 – October 1, 2014. <i>Biologicals</i> , 2016, 44, 37-50.  | 0.5 | 13        |
| 208 | Safety and Immunogenicity of a Tetravalent Dengue Vaccine Candidate in Healthy Children and Adults in Dengue-Endemic Regions: A Randomized, Placebo-Controlled Phase 2 Study. <i>Journal of Infectious Diseases</i> , 2016, 213, 1562-1572. | 1.9 | 72        |
| 209 | HVR1-mediated antibody evasion of highly infectious in vivo adapted HCV in humanised mice. <i>Gut</i> , 2016, 65, 1988-1997.  | 6.1 | 38        |
| 210 | Paradoxical role of antibodies in dengue virus infections: considerations for prophylactic vaccine development. <i>Expert Review of Vaccines</i> , 2016, 15, 467-482.   | 2.0 | 38        |
| 211 | Could an experimental dengue virus infection fail to induce solid immunity against homologous viral challenge in non-human primates?. <i>Archives of Virology</i> , 2016, 161, 465-470.   | 0.9 | 6         |
| 212 | Infectious Diseases of Poverty in Children. <i>Pediatric Clinics of North America</i> , 2016, 63, 37-66.  | 0.9 | 23        |
| 213 | Anti-Infectious Human Vaccination in Historical Perspective. <i>International Reviews of Immunology</i> , 2016, 35, 260-290.  | 1.5 | 18        |
| 214 | Tests in mice of a dengue vaccine candidate made of chimeric Junin virus-like particles and conserved dengue virus envelope sequences. <i>Applied Microbiology and Biotechnology</i> , 2016, 100, 125-133.                                  | 1.7 | 10        |
| 215 | Key concepts, strategies, and challenges in dengue vaccine development: an opportunity for sub-unit candidates?. <i>Expert Review of Vaccines</i> , 2016, 15, 483-495.  | 2.0 | 13        |
| 216 | Vaccination Against Dengue: Challenges and Current Developments. <i>Annual Review of Medicine</i> , 2016, 67, 387-404.  | 5.0 | 46        |
| 217 | Guiding dengue vaccine development using knowledge gained from the success of the yellow fever vaccine. <i>Cellular and Molecular Immunology</i> , 2016, 13, 36-46.   | 4.8 | 23        |
| 218 | Immunogenicity and safety of a tetravalent dengue vaccine in healthy adults in India: A randomized, observer-blind, placebo-controlled phase II trial. <i>Human Vaccines and Immunotherapeutics</i> , 2016, 12, 512-518.                    | 1.4 | 26        |
| 219 | Particulate delivery systems for vaccination against bioterrorism agents and emerging infectious pathogens. <i>Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology</i> , 2017, 9, e1403.                                    | 3.3 | 34        |
| 220 | CYD-TDV dengue vaccine: systematic review and meta-analysis of efficacy, immunogenicity and safety. <i>Journal of Comparative Effectiveness Research</i> , 2017, 6, 165-180.  | 0.6 | 36        |
| 221 | Disease Burden of Dengue in the Philippines: Adjusting for Underreporting by Comparing Active and Passive Dengue Surveillance in Punta Princesa, Cebu City. <i>American Journal of Tropical Medicine and Hygiene</i> , 2017, 96, 16-0488.   | 0.6 | 19        |
| 222 | Vaccines licensed and in clinical trials for the prevention of dengue. <i>Human Vaccines and Immunotherapeutics</i> , 2017, 13, 1059-1072.  | 1.4 | 63        |
| 223 | Prospects for a Zika Virus Vaccine. <i>Immunity</i> , 2017, 46, 176-182.  | 6.6 | 79        |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 224 | The Potential Cost Effectiveness of Different Dengue Vaccination Programmes in Malaysia: A Value-Based Pricing Assessment Using Dynamic Transmission Mathematical Modelling. <i>Pharmacoeconomics</i> , 2017, 35, 575-589.                                  | 1.7 | 20        |
| 225 | Towards development of a universal dengue vaccine – How close are we?. <i>Asian Pacific Journal of Tropical Medicine</i> , 2017, 10, 220-228.   | 0.4 | 29        |
| 226 | Dengue: knowledge gaps, unmet needs, and research priorities. <i>Lancet Infectious Diseases</i> , The, 2017, 17, e88-e100.  | 4.6 | 153       |
| 227 | Patterns of Cellular Immunity Associated with Experimental Infection with rDEN2 <sup>1</sup> 30 (Tonga/74) Support Its Suitability as a Human Dengue Virus Challenge Strain. <i>Journal of Virology</i> , 2017, 91, .                                       | 1.5 | 24        |
| 228 | Prevention and control of dengue – the light at the end of the tunnel. <i>Lancet Infectious Diseases</i> , The, 2017, 17, e79-e87.  | 4.6 | 85        |
| 229 | Disease and economic burdens of dengue. <i>Lancet Infectious Diseases</i> , The, 2017, 17, e70-e78.   | 4.6 | 111       |
| 230 | Chikungunya Virus and Zika Virus Expansion: An Imitation of Dengue Virus. , 2017, , 101-130.  |     | 2         |
| 231 | Two-sex mosquito model for the persistence of <i>Wolbachia</i> . <i>Journal of Biological Dynamics</i> , 2017, 11, 216-237.   | 0.8 | 46        |
| 232 | A dose-response study in mice of a tetravalent vaccine candidate composed of domain III-capsid proteins from dengue viruses. <i>Archives of Virology</i> , 2017, 162, 2247-2256.  | 0.9 | 10        |
| 233 | Vaccination strategies against Zika virus. <i>Current Opinion in Virology</i> , 2017, 23, 59-67.  | 2.6 | 62        |
| 234 | Molecular engineering and plant expression of an immunoglobulin heavy chain scaffold for delivery of a dengue vaccine candidate. <i>Plant Biotechnology Journal</i> , 2017, 15, 1590-1601.  | 4.1 | 31        |
| 235 | Advances in research on Zika virus. <i>Asian Pacific Journal of Tropical Medicine</i> , 2017, 10, 321-331.  | 0.4 | 30        |
| 236 | Evaluation in Mice of the Immunogenicity of a Tetravalent Subunit Vaccine Candidate Against Dengue Virus Using Mucosal and Parenteral Immunization Routes. <i>Viral Immunology</i> , 2017, 30, 350-358.   | 0.6 | 5         |
| 237 | Recent advances in human flavivirus vaccines. <i>Current Opinion in Virology</i> , 2017, 23, 95-101.  | 2.6 | 39        |
| 238 | Original antigenic sin: A comprehensive review. <i>Journal of Autoimmunity</i> , 2017, 83, 12-21.   | 3.0 | 161       |
| 239 | Immunogenicity and Safety of a Booster Injection of DTap-IPV//Hib (Pentaxim) Administered Concomitantly With Tetravalent Dengue Vaccine in Healthy Toddlers 15–18 Months of Age in Mexico. <i>Pediatric Infectious Disease Journal</i> , 2017, 36, 602-608. | 1.1 | 12        |
| 240 | Dengue vaccine acceptance and willingness to pay. <i>Human Vaccines and Immunotherapeutics</i> , 2017, 13, 786-790.   | 1.4 | 30        |
| 241 | ADE and dengue vaccination. <i>Vaccine</i> , 2017, 35, 3910-3912.   | 1.7 | 19        |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 242 | Inhibitors compounds of the flavivirus replication process. <i>Virology Journal</i> , 2017, 14, 95.   | 1.4 | 48        |
| 243 | A recombinant live attenuated tetravalent vaccine for the prevention of dengue. <i>Expert Review of Vaccines</i> , 2017, 16, 671-684.   | 2.0 | 49        |
| 244 | Integrated immunogenicity analysis of a tetravalent dengue vaccine up to 4Ây after vaccination. <i>Human Vaccines and Immunotherapeutics</i> , 2017, 13, 2004-2016.   | 1.4 | 26        |
| 245 | Antiviral Drugs and Other Therapeutic Options for Dengue Virus Infection. <i>Current Treatment Options in Infectious Diseases</i> , 2017, 9, 185-193.   | 0.8 | 2         |
| 246 | Hypoxia enhances antibodyâ€dependent dengue virus infection. <i>EMBO Journal</i> , 2017, 36, 1348-1363.   | 3.5 | 16        |
| 247 | Effects of NS2B-NS3 protease and furin inhibition on West Nile and Dengue virus replication. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 2017, 32, 712-721.   | 2.5 | 34        |
| 248 | Safety and immunogenicity of one versus two doses of Takeda's tetravalent dengue vaccine in children in Asia and Latin America: interim results from a phase 2, randomised, placebo-controlled study. <i>Lancet Infectious Diseases</i> , The, 2017, 17, 615-625. | 4.6 | 72        |
| 249 | Dengue virus serological prevalence and seroconversion rates in children and adults in Medellin, Colombia: implications for vaccine introduction. <i>International Journal of Infectious Diseases</i> , 2017, 58, 27-36.  | 1.5 | 34        |
| 250 | Human CD4 <sup>+</sup> T Cell Responses to an Attenuated Tetravalent Dengue Vaccine Parallel Those Induced by Natural Infection in Magnitude, HLA Restriction, and Antigen Specificity. <i>Journal of Virology</i> , 2017, 91, .                                  | 1.5 | 83        |
| 251 | Epidemic arboviral diseases: priorities for research and public health. <i>Lancet Infectious Diseases</i> , The, 2017, 17, e101-e106.   | 4.6 | 394       |
| 252 | Replication and Excretion of the Live Attenuated Tetravalent Dengue Vaccine CYD-TDV in a Flavivirus-Naive Adult Population: Assessment of Vaccine Viremia and Virus Shedding. <i>Journal of Infectious Diseases</i> , 2017, 216, 834-841.                         | 1.9 | 22        |
| 253 | Live-attenuated tetravalent dengue vaccines: The needs and challenges of post-licensure evaluation of vaccine safety and effectiveness. <i>Vaccine</i> , 2017, 35, 5535-5542.   | 1.7 | 46        |
| 254 | Germline bias dictates cross-serotype reactivity in a common dengue-virus-specific CD8+ T cell response. <i>Nature Immunology</i> , 2017, 18, 1228-1237.  | 7.0 | 36        |
| 255 | Rapid antigen tests for dengue virus serotypes and Zika virus in patient serum. <i>Science Translational Medicine</i> , 2017, 9, .  | 5.8 | 148       |
| 256 | Dengvaxia sensitizes seronegatives to vaccine enhanced disease regardless of age. <i>Vaccine</i> , 2017, 35, 6355-6358.   | 1.7 | 159       |
| 257 | Increased adaptive immune responses and proper feedback regulation protect against clinical dengue. <i>Science Translational Medicine</i> , 2017, 9, .  | 5.8 | 68        |
| 258 | Therapeutic Effects of Monoclonal Antibody against Dengue Virus NS1 in a STAT1 Knockout Mouse Model of Dengue Infection. <i>Journal of Immunology</i> , 2017, 199, 2834-2844.   | 0.4 | 49        |
| 259 | Incidence and risk factors for Dengue virus (DENV) infection in the first 2 years of life in a Brazilian prospective birth cohort. <i>Epidemiology and Infection</i> , 2017, 145, 2971-2979.  | 1.0 | 7         |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 260 | Biodistribution and safety of a live attenuated tetravalent dengue vaccine in the cynomolgus monkey. <i>Vaccine</i> , 2017, 35, 5918-5923.   | 1.7 | 6         |
| 261 | Dengue Virus Hijacks a Noncanonical Oxidoreductase Function of a Cellular Oligosaccharyltransferase Complex. <i>MBio</i> , 2017, 8, .  | 1.8 | 52        |
| 262 | Dengue vaccines. <i>Current Opinion in Infectious Diseases</i> , 2017, 30, 449-454.  | 1.3 | 24        |
| 263 | The immunopathology of dengue and Zika virus infections. <i>Current Opinion in Immunology</i> , 2017, 48, 1-6.   | 2.4 | 38        |
| 264 | Current Status of Dengue Therapeutics Research and Development. <i>Journal of Infectious Diseases</i> , 2017, 215, S96-S102.   | 1.9 | 144       |
| 265 | Achieving safe, effective, and durable Zika virus vaccines: lessons from dengue. <i>Lancet Infectious Diseases</i> , The, 2017, 17, e378-e382.   | 4.6 | 29        |
| 266 | Progress and Works in Progress: Update on Flavivirus Vaccine Development. <i>Clinical Therapeutics</i> , 2017, 39, 1519-1536.  | 1.1 | 95        |
| 267 | Antibodies Against Modified NS1 Wing Domain Peptide Protect Against Dengue Virus Infection. <i>Scientific Reports</i> , 2017, 7, 6975.   | 1.6 | 59        |
| 268 | Moving to a Dengue Preventive Treatment Through New Vaccines. <i>Current Treatment Options in Infectious Diseases</i> , 2017, 9, 347-355.  | 0.8 | 1         |
| 269 | Current status of therapeutic and vaccine approaches against Zika virus. <i>European Journal of Internal Medicine</i> , 2017, 44, 12-18.   | 1.0 | 39        |
| 270 | Dengue burden in India: recent trends and importance of climatic parameters. <i>Emerging Microbes and Infections</i> , 2017, 6, 1-10.  | 3.0 | 133       |
| 271 | Working towards dengue as a vaccine-preventable disease: challenges and opportunities. <i>Expert Opinion on Biological Therapy</i> , 2017, 17, 1193-1199.  | 1.4 | 15        |
| 272 | Emerging Infectious Diseases. <i>Advances in Pediatrics</i> , 2017, 64, 27-71.   | 0.5 | 13        |
| 273 | Bilateral rectus sheath haematoma complicating dengue virus infection in a patient on warfarin for mechanical aortic valve replacement: a case report. <i>BMC Research Notes</i> , 2017, 10, 26.   | 0.6 | 5         |
| 274 | Whither vaccines?. <i>Journal of Infection</i> , 2017, 74, S2-S9.  | 1.7 | 19        |
| 275 | Current management of severe dengue infection. <i>Expert Review of Anti-Infective Therapy</i> , 2017, 15, 67-78.   | 2.0 | 35        |
| 276 | Dengue and Chikungunya. , 2017, , 1119-1122.e1.  |     | 1         |
| 277 | Expression and assembly of cholera toxin B subunit and domain III of dengue virus 2 envelope fusion protein in transgenic potatoes. <i>Protein Expression and Purification</i> , 2017, 139, 57-62. | 0.6 | 12        |



| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 278 | Estimating and mapping the incidence of dengue and chikungunya in Honduras during 2015 using Geographic Information Systems (GIS). <i>Journal of Infection and Public Health</i> , 2017, 10, 446-456.                           | 1.9 | 36        |
| 279 | Antiviral activities of selected antimalarials against dengue virus type 2 and Zika virus. <i>Antiviral Research</i> , 2017, 137, 141-150.  | 1.9 | 77        |
| 280 | Trend and geographic analysis of the prevalence of dengue in Taiwan, 2010–2015. <i>International Journal of Infectious Diseases</i> , 2017, 54, 43-49.  | 1.5 | 36        |
| 281 | Humoral Immune Responses Against Zika Virus Infection and the Importance of Preexisting Flavivirus Immunity. <i>Journal of Infectious Diseases</i> , 2017, 216, S906-S911.  | 1.9 | 34        |
| 282 | Redefining priorities towards graded travel-related infectious disease research. <i>Journal of Travel Medicine</i> , 2017, 24, .  | 1.4 | 22        |
| 283 | Cellular Control of Dengue Virus Replication: Role of Interferon-Inducible Genes. , 0, , .  |     | 3         |
| 284 | Consumer Willingness to Pay for Dengue Vaccine (CYD-TDV, Dengvaxia®) in Brazil; Implications for Future Pricing Considerations. <i>Frontiers in Pharmacology</i> , 2017, 8, 41.   | 1.6 | 31        |
| 285 | Peptides as Therapeutic Agents for Dengue Virus. <i>International Journal of Medical Sciences</i> , 2017, 14, 1342-1359.  | 1.1 | 63        |
| 286 | Prevention and Control Strategies to Counter Dengue Virus Infection. <i>Frontiers in Cellular and Infection Microbiology</i> , 2017, 7, 336.  | 1.8 | 62        |
| 287 | Effective Protection Induced by a Monovalent DNA Vaccine against Dengue Virus (DV) Serotype 1 and a Bivalent DNA Vaccine against DV1 and DV2 in Mice. <i>Frontiers in Cellular and Infection Microbiology</i> , 2017, 7, 175.   | 1.8 | 18        |
| 288 | Clinical Efficacy, Safety, and Immunogenicity of a Live Attenuated Tetravalent Dengue Vaccine (CYD-TDV) in Children: A Systematic Review with Meta-analysis. <i>Frontiers in Immunology</i> , 2017, 8, 863.                     | 2.2 | 23        |
| 289 | Complexity of Human Antibody Response to Dengue Virus: Implication for Vaccine Development. <i>Frontiers in Microbiology</i> , 2017, 8, 1372.   | 1.5 | 25        |
| 290 | Dengue Virus Glycosylation: What Do We Know?. <i>Frontiers in Microbiology</i> , 2017, 8, 1415.   | 1.5 | 70        |
| 291 | Genetic epidemiology of dengue viruses in phase III trials of the CYD tetravalent dengue vaccine and implications for efficacy. <i>ELife</i> , 2017, 6, .   | 2.8 | 36        |
| 293 | Animal models for dengue vaccine development and testing. <i>Clinical and Experimental Vaccine Research</i> , 2017, 6, 104.   | 1.1 | 14        |
| 294 | Seroprevalence of antibodies to dengue and chikungunya viruses in Thailand. <i>PLoS ONE</i> , 2017, 12, e0180560.   | 1.1 | 61        |
| 295 | DNA-immunisation with dengue virus E protein domains I/II, but not domain III, enhances Zika, West Nile and Yellow Fever virus infection. <i>PLoS ONE</i> , 2017, 12, e0181734.   | 1.1 | 34        |
| 296 | Mosquito-Disseminated Insecticide for Citywide Vector Control and Its Potential to Block Arbovirus Epidemics: Entomological Observations and Modeling Results from Amazonian Brazil. <i>PLoS Medicine</i> , 2017, 14, e1002213. | 3.9 | 38        |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 297 | Dissecting the human serum antibody response to secondary dengue virus infections. <i>PLoS Neglected Tropical Diseases</i> , 2017, 11, e0005554.  | 1.3 | 63        |
| 298 | In a randomized trial, the live attenuated tetravalent dengue vaccine TV003 is well-tolerated and highly immunogenic in subjects with flavivirus exposure prior to vaccination. <i>PLoS Neglected Tropical Diseases</i> , 2017, 11, e0005584. | 1.3 | 94        |
| 299 | A systematic review of the economic impact of rapid diagnostic tests for dengue. <i>BMC Health Services Research</i> , 2017, 17, 850.   | 0.9 | 19        |
| 300 | Space and space-time distributions of dengue in a hyper-endemic urban space: the case of Girardot, Colombia. <i>BMC Infectious Diseases</i> , 2017, 17, 512.  | 1.3 | 19        |
| 301 | Seroprevalence of dengue infection in the municipalities of Armenia, Calarcá, La Tebaida and Montenegro in Quindío, 2014. <i>Biomedica</i> , 2017, 37, 34.  | 0.3 | 3         |
| 302 | Dengue-Immune Humans Have Higher Levels of Complement-Independent Enhancing Antibody than Complement-Dependent Neutralizing Antibody. <i>Japanese Journal of Infectious Diseases</i> , 2017, 70, 579-581.                                     | 0.5 | 4         |
| 303 | Regulatory System: Safety and Efficacy of Vaccines. <i>Journal of Vaccines &amp; Vaccination</i> , 2017, 09, .  | 0.3 | 0         |
| 304 | Dengue: The break-bone fever outbreak in Kerala, India. <i>Journal of College of Medical Sciences-Nepal</i> , 2017, 7, 666-669.   | 0.2 | 6         |
| 305 | <i>Systems Vaccinology</i> , 2017, , 101-112.   |     | 0         |
| 306 | Viral Infections in Workers in Hospital and Research Laboratory Settings. <i>Annals of Clinical Microbiology</i> , 2017, 20, 27.  | 0.3 | 2         |
| 307 | The Burden of Dengue and Chikungunya Worldwide: Implications for the Southern United States and California. <i>Annals of Global Health</i> , 2018, 80, 466.   | 0.8 | 70        |
| 308 | Liver involvement in dengue viral infections. <i>Reviews in Medical Virology</i> , 2018, 28, e1971.   | 3.9 | 38        |
| 309 | Unraveling within-host signatures of dengue infection at the population level. <i>Journal of Theoretical Biology</i> , 2018, 446, 79-86.  | 0.8 | 12        |
| 310 | Safety issues from a Phase 3 clinical trial of a live-attenuated chimeric yellow fever tetravalent dengue vaccine. <i>Human Vaccines and Immunotherapeutics</i> , 2018, 14, 2158-2162.  | 1.4 | 55        |
| 311 | Spectrum of activity testing for therapeutics against all four dengue virus serotypes in AG129 mouse models: Proof-of-concept studies with the adenosine nucleoside inhibitor NITD-008. <i>Antiviral Research</i> , 2018, 154, 104-109.       | 1.9 | 12        |
| 312 | Synthetic miRNAs induce dual arboviral-resistance phenotypes in the vector mosquito <i>Aedes aegypti</i> . <i>Communications Biology</i> , 2018, 1, 11.   | 2.0 | 67        |
| 313 | The bright and the dark side of human antibody responses to flaviviruses: lessons for vaccine design. <i>EMBO Reports</i> , 2018, 19, 206-224.  | 2.0 | 188       |
| 314 | Cost-effectiveness of dengue vaccination in ten endemic countries. <i>Vaccine</i> , 2018, 36, 413-420.  | 1.7 | 49        |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 315 | Dengue Hemorrhagic Fever Virus in Saudi Arabia: A Review. <i>Vector-Borne and Zoonotic Diseases</i> , 2018, 18, 75-81.  | 0.6 | 15        |
| 316 | Neutralizing Antibody Correlates Analysis of Tetravalent Dengue Vaccine Efficacy Trials in Asia and Latin America. <i>Journal of Infectious Diseases</i> , 2018, 217, 742-753.  | 1.9 | 80        |
| 317 | Functional Analysis of the Dengue Virus Genome Using an Insertional Mutagenesis Screen. <i>Journal of Virology</i> , 2018, 92, .  | 1.5 | 6         |
| 318 | Impact of Dengue Vaccination on Serological Diagnosis: Insights From Phase III Dengue Vaccine Efficacy Trials. <i>Clinical Infectious Diseases</i> , 2018, 66, 1164-1172.   | 2.9 | 16        |
| 319 | Controversy and debate on dengue vaccine series—paper 2: response to review of a licensed dengue vaccine: inappropriate subgroup analyses and selective reporting may cause harm in mass vaccination programs. <i>Journal of Clinical Epidemiology</i> , 2018, 95, 140-141. | 2.4 | 11        |
| 320 | Characterization and structure-activity relationship analysis of a class of antiviral compounds that directly bind dengue virus capsid protein and are incorporated into virions. <i>Antiviral Research</i> , 2018, 155, 12-19.   | 1.9 | 19        |
| 321 | History, epidemiology and diagnostics of dengue in the American and Brazilian contexts: a review. <i>Parasites and Vectors</i> , 2018, 11, 264.   | 1.0 | 96        |
| 322 | Age-specific seroprevalence of dengue infection in Hong Kong. <i>Journal of Medical Virology</i> , 2018, 90, 1427-1430.   | 2.5 | 3         |
| 323 | Dengue vaccination during pregnancy — An overview of clinical trials data. <i>Vaccine</i> , 2018, 36, 3345-3350.  | 1.7 | 19        |
| 324 | ASEI-SEIR model with vaccination for dengue control in Shah Alam, Malaysia. <i>AIP Conference Proceedings</i> , 2018, , .   | 0.3 | 2         |
| 325 | Estimation of the Optimal Surrogate Based on a Randomized Trial. <i>Biometrics</i> , 2018, 74, 1271-1281.   | 0.8 | 24        |
| 326 | Improvement of the Dengue Virus (DENV) Nonhuman Primate Model via a Reverse Translational Approach Based on Dengue Vaccine Clinical Efficacy Data against DENV-2 and -4. <i>Journal of Virology</i> , 2018, 92, .   | 1.5 | 15        |
| 327 | Delineating the serotype-specific neutralizing antibody response to a live attenuated tetravalent dengue vaccine. <i>Vaccine</i> , 2018, 36, 2403-2410.   | 1.7 | 7         |
| 328 | Beyond mosquitoes—Essential oil toxicity and repellency against bloodsucking insects. <i>Industrial Crops and Products</i> , 2018, 117, 382-392.  | 2.5 | 110       |
| 329 | The use of longitudinal cohorts for studies of dengue viral pathogenesis and protection. <i>Current Opinion in Virology</i> , 2018, 29, 51-61.  | 2.6 | 14        |
| 330 | A Quinoline Compound Inhibits the Replication of Dengue virus Serotypes 1–4 in Vero Cells. <i>Antiviral Therapy</i> , 2018, 23, 385-394.  | 0.6 | 12        |
| 331 | Current status, challenges and perspectives in the development of vaccines against yellow fever, dengue, Zika and chikungunya viruses. <i>Acta Tropica</i> , 2018, 182, 257-263.  | 0.9 | 52        |
| 332 | Rapid response to an emerging infectious disease — Lessons learned from development of a synthetic DNA vaccine targeting Zika virus. <i>Microbes and Infection</i> , 2018, 20, 676-684.   | 1.0 | 25        |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 333 | Four-year safety follow-up of the tetravalent dengue vaccine efficacy randomized controlled trials in Asia and Latin America. <i>Clinical Microbiology and Infection</i> , 2018, 24, 755-763.  | 2.8 | 53        |
| 334 | Clinical development and regulatory points for consideration for second-generation live attenuated dengue vaccines. <i>Vaccine</i> , 2018, 36, 3411-3417.  | 1.7 | 52        |
| 335 | Modelling original antigenic sin in dengue viral infection. <i>Mathematical Medicine and Biology</i> , 2018, 35, 257-272.  | 0.8 | 25        |
| 336 | Bifurcation thresholds and optimal control in transmission dynamics of arboviral diseases. <i>Journal of Mathematical Biology</i> , 2018, 76, 379-427.   | 0.8 | 31        |
| 337 | Which Dengue Vaccine Approach Is the Most Promising, and Should We Be Concerned about Enhanced Disease after Vaccination?. <i>Cold Spring Harbor Perspectives in Biology</i> , 2018, 10, a029462.  | 2.3 | 9         |
| 338 | Which Dengue Vaccine Approach Is the Most Promising, and Should We Be Concerned about Enhanced Disease after Vaccination?. <i>Cold Spring Harbor Perspectives in Biology</i> , 2018, 10, a029520.  | 2.3 | 16        |
| 339 | Which Dengue Vaccine Approach Is the Most Promising, and Should We Be Concerned about Enhanced Disease after Vaccination?. <i>Cold Spring Harbor Perspectives in Biology</i> , 2018, 10, a030700.  | 2.3 | 37        |
| 340 | Spatiotemporal modeling of relative risk of dengue disease in Colombia. <i>Stochastic Environmental Research and Risk Assessment</i> , 2018, 32, 1587-1601.  | 1.9 | 24        |
| 341 | Dependency of Vaccine Efficacy on Preexposure and Age: A Closer Look at a Tetravalent Dengue Vaccine. <i>Clinical Infectious Diseases</i> , 2018, 66, 178-184.   | 2.9 | 28        |
| 342 | Technologies for Making New Vaccines. , 2018, , 1283-1304.e7.  |     | 5         |
| 343 | Outcomes of lupus and rheumatoid arthritis patients with primary dengue infection: A seven-year report from Brazil. <i>Seminars in Arthritis and Rheumatism</i> , 2018, 47, 749-755.   | 1.6 | 10        |
| 344 | Insecticide susceptibility status in Mexican populations of <i>Stegomyia aegypti</i> (= <i>Aedes</i> ) Tj ETQg1 1 0.784314 rgB 0.7 21  | 0.7 | 21        |
| 345 | Using Wolbachia for Dengue Control: Insights from Modelling. <i>Trends in Parasitology</i> , 2018, 34, 102-113.  | 1.5 | 90        |
| 346 | Controversy and debate on dengue vaccine series—paper 1: review of a licensed dengue vaccine: inappropriate subgroup analyses and selective reporting may cause harm in mass vaccination programs. <i>Journal of Clinical Epidemiology</i> , 2018, 95, 137-139.                        | 2.4 | 50        |
| 347 | Immunogenicity and safety of one versus two doses of tetravalent dengue vaccine in healthy children aged 2–17 years in Asia and Latin America: 18-month interim data from a phase 2, randomised, placebo-controlled study. <i>Lancet Infectious Diseases</i> , The, 2018, 18, 162-170. | 4.6 | 59        |
| 348 | Establishing and Utilizing Strategic Partnerships for Vaccine-Preventable Diseases. <i>Infectious Diseases in Clinical Practice</i> , 2018, 26, 252-257.   | 0.1 | 1         |
| 349 | Actividad larvicida de extractos vegetales de la familia Asteraceae y modelación matemática para su uso en el control de poblaciones de <i>Aedes aegypti</i> . <i>Actualidades Biológicas</i> , 2018, 40, .  | 0.1 | 1         |
| 350 | Safety and Immunogenicity of a Tetravalent Dengue DNA Vaccine Administered with a Cationic Lipid-Based Adjuvant in a Phase 1 Clinical Trial. <i>American Journal of Tropical Medicine and Hygiene</i> , 2018, 98, 849-856.   | 0.6 | 62        |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 351 | Emerging and Re-emerging Arboviral Diseases as a Global Health Problem. , 0, , .   |     | 16        |
| 352 | Epidemiological, Serological, and Virological Features of Dengue in Nha Trang City, Vietnam. <i>American Journal of Tropical Medicine and Hygiene</i> , 2018, 98, 402-409.                           | 0.6 | 25        |
| 353 | Vaccine Demand and Willingness-to-pay for Arbovirus Vaccines. <i>Pediatric Infectious Disease Journal</i> , 2018, 37, 1184-1189.   | 1.1 | 17        |
| 354 | Mosquito-Borne Diseases: Prevention Is the Cure for Dengue, Chikungunya and Zika Viruses. <i>Parasitology Research Monographs</i> , 2018, , 235-279.   | 0.4 | 3         |
| 355 | Development of standard clinical endpoints for use in dengue interventional trials: introduction and methodology. <i>BMC Medical Research Methodology</i> , 2018, 18, 134.                           | 1.4 | 5         |
| 356 | The Role of Host Cholesterol During Flavivirus Infection. <i>Frontiers in Cellular and Infection Microbiology</i> , 2018, 8, 388.  | 1.8 | 111       |
| 357 | Mosquito-borne Diseases. <i>Parasitology Research Monographs</i> , 2018, , .   | 0.4 | 14        |
| 358 | Dengue illness indexâ€”A tool to characterize the subjective dengue illness experience. <i>PLoS Neglected Tropical Diseases</i> , 2018, 12, e0006593.  | 1.3 | 4         |
| 359 | Development of a NS2B/NS3 protease inhibition assay using AlphaScreenÂ® beads for screening of anti-dengue activities. <i>Heliyon</i> , 2018, 4, e01023.   | 1.4 | 11        |
| 360 | Periods of high dengue transmission defined by rainfall do not impact efficacy of dengue vaccine in regions of endemic disease. <i>PLoS ONE</i> , 2018, 13, e0207878.                                | 1.1 | 5         |
| 361 | Characterization of recent and minimally passaged Brazilian dengue viruses inducing robust infection in rhesus macaques. <i>PLoS ONE</i> , 2018, 13, e0196311.                                       | 1.1 | 8         |
| 362 | The Development of Peptide-based Antimicrobial Agents against Dengue Virus. <i>Current Protein and Peptide Science</i> , 2018, 19, 998-1010.   | 0.7 | 4         |
| 363 | Vaccine Update: Recent Progress With Novel Vaccines, and New Approaches to Safety Monitoring and Vaccine Shortage. <i>Journal of Clinical Pharmacology</i> , 2018, 58, S123-S139.                    | 1.0 | 6         |
| 364 | CD4 T cell responses to flaviviruses. <i>Journal of Clinical Virology</i> , 2018, 108, 126-131.  | 1.6 | 13        |
| 365 | Ezetimibe inhibits dengue virus infection in Huh-7 cells by blocking the cholesterol transporter Niemannâ€™Pick C1-like 1 receptor. <i>Antiviral Research</i> , 2018, 160, 151-164.                  | 1.9 | 23        |
| 366 | Impact of Dengue Virus Serotype 2 Strain Diversity on Serological Immune Responses to Dengue. <i>ACS Infectious Diseases</i> , 2018, 4, 1705-1717.   | 1.8 | 2         |
| 367 | Safety Follow-up of a Dengue Vaccine When Administered Concomitantly with a Yellow Fever Vaccine in Healthy Toddlers in Colombia. <i>Pediatric Infectious Disease Journal</i> , 2018, 37, 1190-1191. | 1.1 | 3         |
| 368 | The immune response against flaviviruses. <i>Nature Immunology</i> , 2018, 19, 1189-1198.  | 7.0 | 126       |

| #   | ARTICLE  | IF   | CITATIONS |
|-----|--|------|-----------|
| 370 | Dengue-2 virus-like particle (VLP) based vaccine elicits the highest titers of neutralizing antibodies when produced at reduced temperature. <i>Vaccine</i> , 2018, 36, 7728-7736.                                     | 1.7  | 28        |
| 371 | Zika Virus Vaccines: Challenges and Perspectives. <i>Vaccines</i> , 2018, 6, 62.   | 2.1  | 17        |
| 372 | Two-level resolution of relative risk of dengue disease in a hyperendemic city of Colombia. <i>PLoS ONE</i> , 2018, 13, e0203382.  | 1.1  | 12        |
| 373 | Refined efficacy estimates of the Sanofi Pasteur dengue vaccine CYD-TDV using machine learning. <i>Nature Communications</i> , 2018, 9, 3644.  | 5.8  | 15        |
| 374 | Chimeric yellow fever 17D-Zika virus (ChimeriVax-Zika) as a live-attenuated Zika virus vaccine. <i>Scientific Reports</i> , 2018, 8, 13206.  | 1.6  | 35        |
| 375 | Evolutionary history and spatio-temporal dynamics of dengue virus serotypes in an endemic region of Colombia. <i>PLoS ONE</i> , 2018, 13, e0203090.  | 1.1  | 19        |
| 376 | Reconstruction of antibody dynamics and infection histories to evaluate dengue risk. <i>Nature</i> , 2018, 557, 719-723.   | 13.7 | 213       |
| 377 | The dynamic role of dengue cross-reactive immunity: changing the approach to defining vaccine safety and efficacy. <i>Lancet Infectious Diseases</i> , The, 2018, 18, e333-e338.                                       | 4.6  | 15        |
| 378 | Dengue seroprevalence: data from the clinical development of a tetravalent dengue vaccine in 14 countries (2005–2014). <i>Transactions of the Royal Society of Tropical Medicine and Hygiene</i> , 2018, 112, 158-168. | 0.7  | 21        |
| 379 | Nucleocytoplasmic Trafficking of Dengue Non-structural Protein 5 as a Target for Antivirals. <i>Advances in Experimental Medicine and Biology</i> , 2018, 1062, 199-213.   | 0.8  | 11        |
| 380 | Dendritic Cell-Based ELISpot Assay for Assessing T-Cell IFN- $\gamma$ Responses in Human Peripheral Blood Mononuclear Cells to Dengue Envelope Proteins. <i>Methods in Molecular Biology</i> , 2018, 1808, 187-196.    | 0.4  | 1         |
| 381 | Forecasting the effectiveness of indoor residual spraying for reducing dengue burden. <i>PLoS Neglected Tropical Diseases</i> , 2018, 12, e0006570.  | 1.3  | 44        |
| 382 | Dengue vaccine: reliably determining previous exposure. <i>The Lancet Global Health</i> , 2018, 6, e830-e831.  | 2.9  | 27        |
| 383 | Targeting vaccinations for the licensed dengue vaccine: Considerations for serosurvey design. <i>PLoS ONE</i> , 2018, 13, e0199450.  | 1.1  | 11        |
| 384 | Handbook of ELISPOT. <i>Methods in Molecular Biology</i> , 2018, , .   | 0.4  | 0         |
| 385 | Rational Zika vaccine design via the modulation of antigen membrane anchors in chimpanzee adenoviral vectors. <i>Nature Communications</i> , 2018, 9, 2441.  | 5.8  | 69        |
| 386 | <i>Flavivirus</i> serocomplex cross-reactive immunity is protective by activating heterologous memory CD4 T cells. <i>Science Advances</i> , 2018, 4, eaar4297.  | 4.7  | 69        |
| 387 | Assessment of benefits and risks associated with dengue vaccination at the individual and population levels: a dynamic modeling approach. <i>Expert Review of Vaccines</i> , 2018, 17, 753-763.                        | 2.0  | 3         |

| #   | ARTICLE   | IF   | CITATIONS |
|-----|---|------|-----------|
| 388 | Mathematical Analysis of Viral Replication Dynamics and Antiviral Treatment Strategies: From Basic Models to Age-Based Multi-Scale Modeling. <i>Frontiers in Microbiology</i> , 2018, 9, 1546.  | 1.5  | 61        |
| 389 | Pyrethroid insecticides maintain repellent effect on knock-down resistant populations of <i>Aedes aegypti</i> mosquitoes. <i>PLoS ONE</i> , 2018, 13, e0196410.   | 1.1  | 39        |
| 390 | Challenges and opportunities in controlling mosquito-borne infections. <i>Nature</i> , 2018, 559, 490-497.  | 13.7 | 111       |
| 391 | Bistable equilibrium criteria in dengue transmission model for Malaysia. <i>AIP Conference Proceedings</i> , 2018, , .  | 0.3  | 0         |
| 392 | Successful Vaccines. <i>Current Topics in Microbiology and Immunology</i> , 2018, 428, 1-30.  | 0.7  | 22        |
| 393 | The US Military Commitment to Vaccine Development: A Century of Successes and Challenges. <i>Frontiers in Immunology</i> , 2018, 9, 1397.   | 2.2  | 21        |
| 394 | <i>Pichia pastoris</i> -Expressed Bivalent Virus-Like Particulate Vaccine Induces Domain III-Focused Bivalent Neutralizing Antibodies without Antibody-Dependent Enhancement in Vivo. <i>Frontiers in Microbiology</i> , 2017, 8, 2644.           | 1.5  | 29        |
| 395 | Elimination of <i>Falciparum</i> Malaria and Emergence of Severe Dengue: An Independent or Interdependent Phenomenon?. <i>Frontiers in Microbiology</i> , 2018, 9, 1120.  | 1.5  | 4         |
| 396 | Engineered Dengue Virus Domain III Proteins Elicit Cross-Neutralizing Antibody Responses in Mice. <i>Journal of Virology</i> , 2018, 92, .  | 1.5  | 42        |
| 397 | Dengue infection in India: A systematic review and meta-analysis. <i>PLoS Neglected Tropical Diseases</i> , 2018, 12, e0006618.   | 1.3  | 123       |
| 398 | Mathematical assessment of the role of Dengvaxia vaccine on the transmission dynamics of dengue serotypes. <i>Mathematical Biosciences</i> , 2018, 304, 25-47.  | 0.9  | 18        |
| 399 | Discovery of Immunologically Inspired Small Molecules That Target the Viral Envelope Protein. <i>ACS Infectious Diseases</i> , 2018, 4, 1395-1406.  | 1.8  | 27        |
| 400 | Size-dependent neutralizing activity of gold nanoparticle-based subunit vaccine against dengue virus. <i>Acta Biomaterialia</i> , 2018, 78, 224-235.  | 4.1  | 43        |
| 401 | Using a Virion Assembly-Defective Dengue Virus as a Vaccine Approach. <i>Journal of Virology</i> , 2018, 92, .  | 1.5  | 13        |
| 402 | Viral genetic diversity and protective efficacy of a tetravalent dengue vaccine in two phase 3 trials. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, E8378-E8387.                           | 3.3  | 57        |
| 403 | Molecular basis for dengue virus broad cross-neutralization by humanized monoclonal antibody 513. <i>Scientific Reports</i> , 2018, 8, 8449.  | 1.6  | 14        |
| 404 | Limiting global-mean temperature increase to 1.5°C could reduce the incidence and spatial spread of dengue fever in Latin America. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, 6243-6248. | 3.3  | 42        |
| 405 | Dengue envelope-based "four-in-one" virus-like particles produced using <i>Pichia pastoris</i> induce enhancement-lacking, domain III-directed tetravalent neutralising antibodies in mice. <i>Scientific Reports</i> , 2018, 8, 8643.            | 1.6  | 24        |

| #   | ARTICLE  | IF   | CITATIONS |
|-----|--|------|-----------|
| 406 | Effect of Dengue Serostatus on Dengue Vaccine Safety and Efficacy. <i>New England Journal of Medicine</i> , 2018, 379, 327-340.  | 13.9 | 557       |
| 407 | Economic Analyses of Vaccine Policies. , 2018, , 1532-1546.e7.   |      | 0         |
| 408 | Vaccine Safety. , 2018, , 1584-1600.e10.   |      | 10        |
| 409 | Dengue knowledge, attitudes and practices and their impact on community-based vector control in rural Cambodia. <i>PLoS Neglected Tropical Diseases</i> , 2018, 12, e0006268.  | 1.3  | 51        |
| 410 | A tetravalent virus-like particle vaccine designed to display domain III of dengue envelope proteins induces multi-serotype neutralizing antibodies in mice and macaques which confer protection against antibody dependent enhancement in AG129 mice. <i>PLoS Neglected Tropical Diseases</i> , 2018, 12, e0006191. | 1.3  | 67        |
| 411 | Dengue Vaccines. , 2018, , 241-251.e6.   |      | 2         |
| 413 | Structural and Functional Properties of the Capsid Protein of Dengue and Related Flavivirus. <i>International Journal of Molecular Sciences</i> , 2019, 20, 3870.  | 1.8  | 22        |
| 414 | A model to study the inhibition of nsP2B-nsP3 protease of dengue virus with imidazole, oxazole, triazole thiazole, and thiazolidine based scaffolds. <i>Heliyon</i> , 2019, 5, e02124.   | 1.4  | 30        |
| 415 | Nonparametric inference for immune response thresholds of risk in vaccine studies. <i>Annals of Applied Statistics</i> , 2019, 13, 1147-1165.  | 0.5  | 4         |
| 416 | Dengue Mosaic Vaccines Enhance Cellular Immunity and Expand the Breadth of Neutralizing Antibody Against All Four Serotypes of Dengue Viruses in Mice. <i>Frontiers in Immunology</i> , 2019, 10, 1429.  | 2.2  | 6         |
| 417 | T Cell Responses Induced by DNA Vaccines Based on the DENV2 E and NS1 Proteins in Mice: Importance in Protection and Immunodominant Epitope Identification. <i>Frontiers in Immunology</i> , 2019, 10, 1522.   | 2.2  | 20        |
| 418 | In vitro and in silico Models to Study Mosquito-Borne Flavivirus Neuropathogenesis, Prevention, and Treatment. <i>Frontiers in Cellular and Infection Microbiology</i> , 2019, 9, 223.   | 1.8  | 10        |
| 419 | Larvicidal and Enzymatic Inhibition Effects of <i>Annona muricata</i> Seed Extract and Main Constituent Annonacin against <i>Aedes aegypti</i> and <i>Aedes albopictus</i> (Diptera: Culicidae). <i>Pharmaceuticals</i> , 2019, 12, 112.   | 1.7  | 12        |
| 420 | Model-based assessment of public health impact and cost-effectiveness of dengue vaccination following screening for prior exposure. <i>PLoS Neglected Tropical Diseases</i> , 2019, 13, e0007482.  | 1.3  | 23        |
| 421 | Cost effectiveness of dengue vaccination following pre-vaccination serological screening in Sri Lanka. <i>International Journal of Technology Assessment in Health Care</i> , 2019, 35, 427-435.   | 0.2  | 7         |
| 422 | Evaluation of rapid diagnostic tests and conventional enzyme-linked immunosorbent assays to determine prior dengue infection. <i>Journal of Travel Medicine</i> , 2019, 26, .  | 1.4  | 39        |
| 423 | Dengue NS2A Protein Orchestrates Virus Assembly. <i>Cell Host and Microbe</i> , 2019, 26, 606-622.e8.  | 5.1  | 68        |
| 424 | A review of Dengvaxia®: development to deployment. <i>Human Vaccines and Immunotherapeutics</i> , 2019, 15, 2295-2314.   | 1.4  | 206       |



| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 425 | Complete chloroplast genome of a rare deciduous tree species, <i>Sinomanglietia glauca</i> (Magnoliaceae). Mitochondrial DNA Part B: Resources, 2019, 4, 3212-3213.  | 0.2 | 1         |
| 426 | Output characteristic analysis and delivery line capacity exploration of large-scale offshore wind power. Journal of Physics: Conference Series, 2019, 1311, 012001.   | 0.3 | 0         |
| 427 | Monoclonal antibody-based capture ELISA in the diagnosis of previous dengue infection. Virology Journal, 2019, 16, 125.  | 1.4 | 7         |
| 428 | Spatial patterns in soil physicochemical and microbiological properties in a grassland adjacent to a newly built lake. MicrobiologyOpen, 2019, 8, e912.  | 1.2 | 3         |
| 429 | Introductory Chapter: The Journey of Vaccines - The Past and the Present. , 2019, , .  |     | 1         |
| 430 | Increased Mosquito Midgut Infection by Dengue Virus Recruitment of Plasmin Is Blocked by an Endogenous Kazal-type Inhibitor. IScience, 2019, 21, 564-576.  | 1.9 | 10        |
| 431 | Persistent Dengue Infection in an Immunosuppressed Patient Reveals the Roles of Humoral and Cellular Immune Responses in Virus Clearance. Cell Host and Microbe, 2019, 26, 601-605.e3.                             | 5.1 | 20        |
| 432 | Quaternary Solar Cells with 12.5% Efficiency Enabled with Non-Fullerene and Fullerene Acceptor Guests to Improve Open Circuit Voltage and Film Morphology. Macromolecular Rapid Communications, 2019, 40, 1900353. | 2.0 | 8         |
| 433 | In vivo analysis of renal epithelial cells in zebrafish. Methods in Cell Biology, 2019, 154, 163-181.  | 0.5 | 5         |
| 434 | Systematic review of dengue vaccine efficacy. BMC Infectious Diseases, 2019, 19, 750.  | 1.3 | 40        |
| 435 | Serostatus testing and dengue vaccine cost-benefit thresholds. Journal of the Royal Society Interface, 2019, 16, 20190234.   | 1.5 | 12        |
| 436 | Human T Cell Response to Dengue Virus Infection. Frontiers in Immunology, 2019, 10, 2125.  | 2.2 | 102       |
| 437 | Molecular basis of dengue virus serotype 2 morphological switch from 29°C to 37°C. PLoS Pathogens, 2019, 15, e1007996.   | 2.1 | 25        |
| 438 | Seeking Flavivirus Cross-Protective Immunity. Frontiers in Immunology, 2019, 10, 2260.   | 2.2 | 20        |
| 439 | T-Cell Response to Viral Hemorrhagic Fevers. Vaccines, 2019, 7, 11.  | 2.1 | 30        |
| 440 | Biased efficacy estimates in phase-III dengue vaccine trials due to heterogeneous exposure and differential detectability of primary infections across trial arms. PLoS ONE, 2019, 14, e0210041.                   | 1.1 | 606       |
| 441 | Dengue. Lancet, The, 2019, 393, 350-363.   | 6.3 | 420       |
| 442 | Aiming at the heart: the capsid protein of dengue virus as a vaccine candidate. Expert Review of Vaccines, 2019, 18, 161-173.  | 2.0 | 10        |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 443 | Emerging and Reemerging <i>Aedes</i> -Transmitted Arbovirus Infections in the Region of the Americas: Implications for Health Policy. <i>American Journal of Public Health</i> , 2019, 109, 387-392.                                    | 1.5 | 57        |
| 444 | Cross-Protection Against Four Serotypes of Dengue Virus in Mice Conferred by a Zika DNA Vaccine. <i>Frontiers in Cellular and Infection Microbiology</i> , 2019, 9, 147.  | 1.8 | 16        |
| 446 | Dengue: An Expanding Neglected Tropical Disease. <i>Neglected Tropical Diseases</i> , 2019, , 65-84.  | 0.4 | 3         |
| 447 | Lemongrass and Cinnamon Bark: Plant Essential Oil Blend as a Spatial Repellent for Mosquitoes in a Field Setting. <i>Journal of Medical Entomology</i> , 2019, 56, 1346-1352.   | 0.9 | 21        |
| 448 | Economic Evaluations of Dengue Vaccination in the Southeast Asia Region: Evidence From a Systematic Review. <i>Value in Health Regional Issues</i> , 2019, 18, 132-144.   | 0.5 | 17        |
| 449 | Detection of post-vaccination enhanced dengue virus infection in macaques: An improved model for early assessment of dengue vaccines. <i>PLoS Pathogens</i> , 2019, 15, e1007721.   | 2.1 | 27        |
| 450 | Attenuation of a dengue virus replicon by codon deoptimization of nonstructural genes. <i>Vaccine</i> , 2019, 37, 2857-2863.  | 1.7 | 14        |
| 451 | Resistance Status to Deltamethrin, Permethrin, and Temephos Along With Preliminary Resistance Mechanism in <i>Aedes aegypti</i> (Diptera: Culicidae) From Punjab, Pakistan. <i>Journal of Medical Entomology</i> , 2019, 56, 1304-1311. | 0.9 | 19        |
| 452 | Sensitivity and negative predictive value for a rapid dengue test. <i>Lancet Infectious Diseases</i> , The, 2019, 19, 465-466.  | 4.6 | 16        |
| 453 | Systematic review of health economic evaluation studies of dengue vaccines. <i>Vaccine</i> , 2019, 37, 2298-2310.   | 1.7 | 12        |
| 454 | Key Amino Acid Substitution for Infection-Enhancing Activity-Free Designer Dengue Vaccines. <i>IScience</i> , 2019, 13, 125-137.  | 1.9 | 4         |
| 455 | Novel Flavivirus Antiviral That Targets the Host Nuclear Transport Importin $\beta 1$ Heterodimer. <i>Cells</i> , 2019, 8, 281.   | 1.8 | 31        |
| 456 | Effect of Adjuvant Homeopathy with Usual Care in Management of Thrombocytopenia Due to Dengue: A Comparative Cohort Study. <i>Homeopathy</i> , 2019, 108, 150-157.  | 0.5 | 20        |
| 457 | Efficacy, immunogenicity and safety of a recombinant tetravalent dengue vaccine (CYD-TDV) in children aged 2–17 years: systematic review and meta-analysis. <i>BMJ Open</i> , 2019, 9, e019368.   | 0.8 | 10        |
| 458 | Dengue in India: Towards a better understanding of priorities and progress. <i>International Journal of Infectious Diseases</i> , 2019, 84, S1-S3.  | 1.5 | 8         |
| 459 | Genomic signature of early T-cell response is associated with lower antibody titer threshold for sterilizing immunity. <i>Antiviral Research</i> , 2019, 166, 35-41.  | 1.9 | 4         |
| 460 | Cost of illness and program of dengue: A systematic review. <i>PLoS ONE</i> , 2019, 14, e0211401.   | 1.1 | 30        |
| 461 | Neglected tropical diseases in children: An assessment of gaps in research prioritization. <i>PLoS Neglected Tropical Diseases</i> , 2019, 13, e0007111.  | 1.3 | 23        |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 462 | Identification of small molecule inhibitors targeting the Zika virus envelope protein. <i>Antiviral Research</i> , 2019, 164, 147-153.  | 1.9 | 14        |
| 463 | Long-term immunogenicity and safety of tetravalent dengue vaccine (CYD-TDV) in healthy populations in Singapore and Vietnam: 4-year follow-up of randomized, controlled, phase II trials. <i>Human Vaccines and Immunotherapeutics</i> , 2019, 15, 2315-2327. | 1.4 | 11        |
| 464 | Mathematical modeling of dengue epidemic: control methods and vaccination strategies. <i>Theory in Biosciences</i> , 2019, 138, 223-239.  | 0.6 | 42        |
| 465 | Homologs of Human Dengue-Resistance Genes, FKBP1B and ATCAY, Confer Antiviral Resistance in <i>Aedes aegypti</i> Mosquitoes. <i>Insects</i> , 2019, 10, 46.   | 1.0 | 4         |
| 466 | Bioethics of establishing a CHIM model for dengue vaccine development. <i>International Journal of Infectious Diseases</i> , 2019, 84, S74-S79.   | 1.5 | 13        |
| 467 | The Burden of Dengue Illness and Its Economics Costs in the Americas: A Review on the Most Affected Countries. , 2019, , .  |     | 1         |
| 468 | Recent advances in understanding dengue. <i>F1000Research</i> , 2019, 8, 1279.  | 0.8 | 63        |
| 469 | A dengue fever predicting model based on Baidu search index data and climate data in South China. <i>PLoS ONE</i> , 2019, 14, e0226841.   | 1.1 | 25        |
| 470 | Dengue Vaccine Booster in Healthy Adolescents and Adults in Latin America. <i>Pediatric Infectious Disease Journal</i> , 2019, 38, e90-e95.   | 1.1 | 5         |
| 471 | Considering Genomic and Immunological Correlates of Protection for a Dengue Intervention. <i>Vaccines</i> , 2019, 7, 203.   | 2.1 | 2         |
| 472 | Novel bioactive peptides demonstrating anti-dengue virus activity isolated from the Asian medicinal plant <i>Acacia Catechu</i> . <i>Chemical Biology and Drug Design</i> , 2019, 93, 100-109.  | 1.5 | 37        |
| 473 | Deliberations of the Strategic Advisory Group of Experts on Immunization on the use of CYD-TDV dengue vaccine. <i>Lancet Infectious Diseases</i> , The, 2019, 19, e31-e38.  | 4.6 | 120       |
| 474 | Going Viral 2019. <i>Dermatologic Clinics</i> , 2019, 37, 95-105.   | 1.0 | 36        |
| 475 | Small Molecules Targeting the Flavivirus E Protein with Broad-Spectrum Activity and Antiviral Efficacy <i>in Vivo</i> . <i>ACS Infectious Diseases</i> , 2019, 5, 460-472.  | 1.8 | 29        |
| 476 | Emerging arboviruses and implications for pediatric transplantation: A review. <i>Pediatric Transplantation</i> , 2019, 23, e13303.   | 0.5 | 9         |
| 477 | Should travellers be offered vaccination against the dengue virus?. <i>Travel Medicine and Infectious Disease</i> , 2019, 27, 2-4.  | 1.5 | 1         |
| 478 | Characterization of recombinant yellow fever-dengue vaccine viruses with human monoclonal antibodies targeting key conformational epitopes. <i>Vaccine</i> , 2019, 37, 4601-4609.   | 1.7 | 5         |
| 479 | Magnitude and Functionality of the NS1-Specific Antibody Response Elicited by a Live-Attenuated Tetravalent Dengue Vaccine Candidate. <i>Journal of Infectious Diseases</i> , 2020, 221, 867-877.   | 1.9 | 27        |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 480 | Dengue Vaccine, A Double-Edged Sword. <i>Journal of the Pediatric Infectious Diseases Society</i> , 2020, 9, 107-109.   | 0.6 | 4         |
| 481 | Inference on treatment effect modification by biomarker response in a three-phase sampling design. <i>Biostatistics</i> , 2020, 21, 545-560.  | 0.9 | 7         |
| 482 | Undifferentiated Tropical Viral Fevers in Latin America. , 2020, , 219-240.   |     | 0         |
| 483 | Hybrid clinical trials to generate real-world evidence: design considerations from a sponsor's perspective. <i>Contemporary Clinical Trials</i> , 2020, 94, 105856.   | 0.8 | 21        |
| 484 | AI- modelling of molecular identification and feminization of wolbachia infected <i>Aedes aegypti</i> . <i>Progress in Biophysics and Molecular Biology</i> , 2020, 150, 104-111.   | 1.4 | 11        |
| 485 | Prevalence of dengue antibodies in healthy children and adults in different Colombian endemic areas. <i>International Journal of Infectious Diseases</i> , 2020, 91, 9-16.  | 1.5 | 20        |
| 486 | Exploring the role of a recently licensed dengue vaccine in Australian travellers. <i>Medical Journal of Australia</i> , 2020, 212, 102.  | 0.8 | 1         |
| 487 | A cohort study to assess the incidence of dengue, Brazil, 2014-2018. <i>Acta Tropica</i> , 2020, 204, 105313.   | 0.9 | 15        |
| 488 | The first characterization of a cystatin and a cathepsin L-like peptidase from <i>Aedes aegypti</i> and their possible role in DENV infection by the modulation of apoptosis. <i>International Journal of Biological Macromolecules</i> , 2020, 146, 141-149.   | 3.6 | 4         |
| 489 | The potential impact of dengue vaccination with, and without, pre-vaccination screening. <i>Vaccine</i> , 2020, 38, 1363-1369.  | 1.7 | 21        |
| 490 | The Effects of Japanese Encephalitis Vaccine and Accelerated Dosing Scheduling on the Immunogenicity of the Chimeric Yellow Fever Derived Tetravalent Dengue Vaccine: A Phase II, Randomized, Open-Label, Single-Center Trial in Adults Aged 18 to 45 Years in the United States. <i>Journal of Infectious Diseases</i> , 2020, 221, 1057-1069. | 1.9 | 6         |
| 491 | Evaluation of dengue serological tests available in Puerto Rico for identification of prior dengue infection for prevaccination screening. <i>Diagnostic Microbiology and Infectious Disease</i> , 2020, 96, 114918.  | 0.8 | 15        |
| 492 | Economic and political aspects of Dengue virus disease. , 2020, , 151-158.  |     | 1         |
| 493 | Treatment and therapeutic agents and vaccines. , 2020, , 159-184.   |     | 0         |
| 494 | Simultaneous Inference of Treatment Effect Modification by Intermediate Response Endpoint Principal Strata with Application to Vaccine Trials. <i>International Journal of Biostatistics</i> , 2020, 16, .  | 0.4 | 4         |
| 495 | Immune Response Persistence and Safety of a Booster Dose of the Tetravalent Dengue Vaccine in Adolescents and Adults Who Previously Completed the 3-dose Schedule 4-5 Years Earlier in Latin America. <i>Pediatric Infectious Disease Journal</i> , 2020, 39, 961-968.  | 1.1 | 6         |
| 496 | Historical discourse on the development of the live attenuated tetravalent dengue vaccine candidate TV003/TV005. <i>Current Opinion in Virology</i> , 2020, 43, 79-87.  | 2.6 | 19        |
| 497 | Efficacy after 1 and 2 doses of CYD-TDV in dengue endemic areas by dengue serostatus. <i>Vaccine</i> , 2020, 38, 6472-6477.   | 1.7 | 14        |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 498 | Modeling the potential of wAu-Wolbachia strain invasion in mosquitoes to control Aedes-borne arboviral infections. <i>Scientific Reports</i> , 2020, 10, 16812.  | 1.6 | 17        |
| 499 | A cocrystal structure of dengue capsid protein in complex of inhibitor. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 17992-18001.   | 3.3 | 18        |
| 500 | Antibody-Dependent Enhancement: A Challenge for Developing a Safe Dengue Vaccine. <i>Frontiers in Cellular and Infection Microbiology</i> , 2020, 10, 572681.  | 1.8 | 103       |
| 501 | The Impact of Serotype Cross-Protection on Vaccine Trials: DENVax as a Case Study. <i>Vaccines</i> , 2020, 8, 674.   | 2.1 | 18        |
| 502 | Use of Animal Models in Studying Roles of Antibodies and Their Secretion Cells in Dengue Vaccine Development. <i>Viruses</i> , 2020, 12, 1261.   | 1.5 | 1         |
| 503 | Can phytotherapy with polyphenols serve as a powerful approach for the prevention and therapy tool of novel coronavirus disease 2019 (COVID-19)?. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2020, 319, E689-E708. | 1.8 | 51        |
| 504 | Dengue: A Minireview. <i>Viruses</i> , 2020, 12, 829.  | 1.5 | 149       |
| 505 | Modified mRNA-LNP Vaccines Confer Protection against Experimental DENV-2 Infection in Mice. <i>Molecular Therapy - Methods and Clinical Development</i> , 2020, 18, 702-712.   | 1.8 | 38        |
| 506 | Sequential immunization induces strong and broad immunity against all four dengue virus serotypes. <i>Npj Vaccines</i> , 2020, 5, 68.  | 2.9 | 13        |
| 507 | Evaluation of treatment effect modification by biomarkers measured pre- and post-randomization in the presence of non-monotone missingness. <i>Biostatistics</i> , 2022, 23, 541-557.  | 0.9 | 2         |
| 508 | Dengue: current state one year before WHO 2010–2020 goals. <i>Acta Clinica Belgica</i> , 2022, 77, 436-444.  | 0.5 | 23        |
| 509 | Relative contribution of nonstructural protein 1 in dengue pathogenesis. <i>Journal of Experimental Medicine</i> , 2020, 217, .  | 4.2 | 18        |
| 510 | Dengue virus 4: the “black sheep” of the family?. <i>Expert Review of Vaccines</i> , 2020, 19, 807-815.  | 2.0 | 3         |
| 511 | Residual Larvicidal Activity of Quinones against <i>Aedes aegypti</i> . <i>Molecules</i> , 2020, 25, 3978.   | 1.7 | 25        |
| 512 | Anti-Flavivirus Vaccines: Review of the Present Situation and Perspectives of Subunit Vaccines Produced in <i>Escherichia coli</i> . <i>Vaccines</i> , 2020, 8, 492.   | 2.1 | 18        |
| 513 | Schools as centers for health educational initiatives, health behavior research and risk behavior for dengue infection in school children and community members: a systematic review. <i>Health Education Research</i> , 2020, 35, 376-395.    | 1.0 | 9         |
| 514 | Entry Inhibitors: Efficient Means to Block Viral Infection. <i>Journal of Membrane Biology</i> , 2020, 253, 425-444.   | 1.0 | 35        |
| 515 | Multifunctional T cell response in convalescent patients two years after ZIKV infection. <i>Journal of Leukocyte Biology</i> , 2020, 108, 1265-1277.   | 1.5 | 3         |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 516 | Optimal vaccination strategy for dengue transmission in Kupang city, Indonesia. <i>Heliyon</i> , 2020, 6, e05345.   | 1.4 | 18        |
| 517 | Changepoint inference in the presence of missing covariates for principal surrogate evaluation in vaccine trials. <i>Biometrika</i> , 2021, 108, 829-843.   | 1.3 | 0         |
| 518 | System biology approach to identify critical host genes for dengue infection. , 2020, , .   |     | 0         |
| 519 | On the Use of Markov Models in Pharmacoeconomics: Pros and Cons and Implications for Policy Makers. <i>Frontiers in Public Health</i> , 2020, 8, 569500.  | 1.3 | 20        |
| 520 | Modelling the Use of Vaccine and Wolbachia on Dengue Transmission Dynamics. <i>Tropical Medicine and Infectious Disease</i> , 2020, 5, 78.  | 0.9 | 11        |
| 521 | Advancements in developing an effective and preventive dengue vaccine. <i>Future Virology</i> , 2020, 15, 127-138.  | 0.9 | 3         |
| 522 | The Effects of Pre-Existing Antibodies on Live-Attenuated Viral Vaccines. <i>Viruses</i> , 2020, 12, 520.   | 1.5 | 47        |
| 523 | Dengue vaccine: a key for prevention. <i>Expert Review of Vaccines</i> , 2020, 19, 499-506.   | 2.0 | 1         |
| 524 | A Simple and High-Throughput ELISA-Based Neutralization Assay for the Determination of Anti-Flavivirus Neutralizing Antibodies. <i>Vaccines</i> , 2020, 8, 297.   | 2.1 | 10        |
| 525 | Microneutralization assay titer correlates analysis in two phase 3 trials of the CYD-TDV tetravalent dengue vaccine in Asia and Latin America. <i>PLoS ONE</i> , 2020, 15, e0234236.  | 1.1 | 9         |
| 526 | Anti-dengue virus serotype 2 activity of tannins from porcupine dates. <i>Chinese Medicine</i> , 2020, 15, 49.  | 1.6 | 7         |
| 527 | Adaptive Immunity to Dengue Virus: Slippery Slope or Solid Ground for Rational Vaccine Design?. <i>Pathogens</i> , 2020, 9, 470.  | 1.2 | 10        |
| 528 | Effect of an ecosystem-centered community participation programme on the incidence of dengue. A field randomized, controlled trial. <i>International Journal of Public Health</i> , 2020, 65, 249-255.                                      | 1.0 | 4         |
| 529 | Secondary Analysis of the Efficacy and Safety Trial Data of the Tetravalent Dengue Vaccine in Children and Adolescents in Colombia. <i>Pediatric Infectious Disease Journal</i> , 2020, 39, e30-e36.  | 1.1 | 2         |
| 530 | <sc><i>Aedes aegypti</i></sc>lachesin protein binds to the domain III of envelop protein of Dengue virus and inhibits viral replication. <i>Cellular Microbiology</i> , 2020, 22, e13200.   | 1.1 | 3         |
| 531 | Assessment of the long-term efficacy of a dengue vaccine against symptomatic, virologically-confirmed dengue disease by baseline dengue serostatus. <i>Vaccine</i> , 2020, 38, 3531-3536.   | 1.7 | 12        |
| 532 | Safety and immunogenicity of the tetravalent, live-attenuated dengue vaccine Butantan-DV in adults in Brazil: a two-step, double-blind, randomised placebo-controlled phase 2 trial. <i>Lancet Infectious Diseases</i> , 2020, 20, 839-850. | 4.6 | 50        |
| 533 | Dengue Endemicity, Force of Infection, and Variation in Transmission Intensity in 13 Endemic Countries. <i>Journal of Infectious Diseases</i> , 2022, 225, 75-83.   | 1.9 | 11        |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 534 | Cross-reactivity reduced dengue virus 2 vaccine has no cross-protection against heterotypic dengue viruses. <i>Future Virology</i> , 2020, 15, 79-90.   | 0.9 | 0         |
| 535 | Antibody-Dependent Enhancement of Viral Infections. , 2020, , 9-41.   |     | 43        |
| 536 | Anti-dengue Vaccines: From Development to Clinical Trials. <i>Frontiers in Immunology</i> , 2020, 11, 1252.   | 2.2 | 31        |
| 537 | A dose-response study in mice of a tetravalent recombinant dengue envelope domain III protein secreted from insect cells. <i>Infection, Genetics and Evolution</i> , 2020, 85, 104427.                                  | 1.0 | 0         |
| 538 | Dengue: Status of current and underâ€development vaccines. <i>Reviews in Medical Virology</i> , 2020, 30, e2101.  | 3.9 | 49        |
| 539 | Addition of Partial Envelope Domain II into Envelope Domain III of Dengue Virus Antigen Potentiates the Induction of Virus-Neutralizing Antibodies and Induces Protective Immunity. <i>Vaccines</i> , 2020, 8, 88.      | 2.1 | 9         |
| 540 | Design and production of dengue virus chimeric proteins useful for developing tetravalent vaccines. <i>Vaccine</i> , 2020, 38, 2005-2015.   | 1.7 | 3         |
| 541 | Mapping global variation in dengue transmission intensity. <i>Science Translational Medicine</i> , 2020, 12, .  | 5.8 | 131       |
| 542 | Understanding Flavivirus Capsid Protein Functions: The Tip of the Iceberg. <i>Pathogens</i> , 2020, 9, 42.  | 1.2 | 34        |
| 543 | Defeat Dengue and Zika Viruses With a One-Two Punch of Vaccine and Vector Blockade. <i>Frontiers in Microbiology</i> , 2020, 11, 362.   | 1.5 | 9         |
| 544 | Design, synthesis and biological evaluation of spiropyrazolopyridone derivatives as potent dengue virus inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2020, 30, 127162.                               | 1.0 | 8         |
| 545 | Designing effective control of dengue with combined interventions. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 3319-3325.                                       | 3.3 | 29        |
| 546 | The Cellular Impact of the ZIKA Virus on Male Reproductive Tract Immunology and Physiology. <i>Cells</i> , 2020, 9, 1006.   | 1.8 | 20        |
| 547 | Treatment seeking behavior and associated factors of suspected dengue fever among Shan people in eastern Shan special region IV, Myanmar: a cross-sectional study. <i>BMC Health Services Research</i> , 2020, 20, 318. | 0.9 | 13        |
| 548 | Route of inoculation and mosquito vector exposure modulate dengue virus replication kinetics and immune responses in rhesus macaques. <i>PLoS Neglected Tropical Diseases</i> , 2020, 14, e0008191.                     | 1.3 | 20        |
| 549 | Two Is Better Than One: Evidence for T-Cell Cross-Protection Between Dengue and Zika and Implications on Vaccine Design. <i>Frontiers in Immunology</i> , 2020, 11, 517.  | 2.2 | 31        |
| 550 | CYD Tetravalent Dengue Vaccine Performance by Baseline Immune Profile (Monotypic/Multitypic) in Dengue-Seropositive Individuals. <i>Clinical Infectious Diseases</i> , 2021, 72, 1730-1737.                             | 2.9 | 5         |
| 551 | A 5â€year study of dengue seropositivity among suspected cases attending a teaching hospital of Northâ€Western region of India. <i>Journal of Medical Virology</i> , 2021, 93, 3338-3343.                               | 2.5 | 10        |

| #   | ARTICLE   | IF   | CITATIONS |
|-----|---|------|-----------|
| 552 | Learning from the past: development of safe and effective COVID-19 vaccines. <i>Nature Reviews Microbiology</i> , 2021, 19, 211-219.  | 13.6 | 126       |
| 553 | Probability of Success and Timelines for the Development of Vaccines for Emerging and Reemerged Viral Infectious Diseases. <i>Annals of Internal Medicine</i> , 2021, 174, 326-334.   | 2.0  | 11        |
| 554 | Accuracy and efficacy of pre-dengue vaccination screening for previous dengue infection with five commercially available immunoassays: a retrospective analysis of phase 3 efficacy trials. <i>Lancet Infectious Diseases</i> , The, 2021, 21, 529-536.               | 4.6  | 15        |
| 555 | Immunogenicity and safety of simplified vaccination schedules for the CYD-TDV dengue vaccine in healthy individuals aged 9 to 50 years (CYD65): a randomised, controlled, phase 2, non-inferiority study. <i>Lancet Infectious Diseases</i> , The, 2021, 21, 517-528. | 4.6  | 9         |
| 556 | An update on dengue vaccine development, challenges, and future perspectives. <i>Expert Opinion on Drug Discovery</i> , 2021, 16, 47-58.  | 2.5  | 27        |
| 557 | Zika and Dengue Interactions in the Context of a Large Dengue Vaccine Clinical Trial in Latin America. <i>American Journal of Tropical Medicine and Hygiene</i> , 2021, 104, 136-144.   | 0.6  | 2         |
| 558 | Dengue Vaccine Effectiveness: A Population Cohort Study from 2016 to 2019, in Paranaíba, Brazil. <i>SSRN Electronic Journal</i> , 0, , .  | 0.4  | 0         |
| 559 | Antibody affinity versus dengue morphology influences neutralization. <i>PLoS Pathogens</i> , 2021, 17, e1009331.   | 2.1  | 8         |
| 560 | COVID-19, Chikungunya, Dengue and Zika Diseases: An Analytical Platform Based on MALDI-TOF MS, IR Spectroscopy and RT-qPCR for Accurate Diagnosis and Accelerate Epidemics Control. <i>Microorganisms</i> , 2021, 9, 708.   | 1.6  | 9         |
| 561 | Structural and biochemical insights into flavivirus proteins. <i>Virus Research</i> , 2021, 296, 198343.  | 1.1  | 6         |
| 563 | Analysis of Hospitalized and Severe Dengue Cases Over the 6 years of Follow-up of the Tetravalent Dengue Vaccine (CYD-TDV) Efficacy Trials in Asia and Latin America. <i>Clinical Infectious Diseases</i> , 2021, 73, 1003-1012.                                      | 2.9  | 11        |
| 564 | Discriminating arboviral species. <i>Journal of General Virology</i> , 2021, 102, .   | 1.3  | 1         |
| 565 | Enhanced dengue vaccine virus replication and neutralizing antibody responses in immune primed rhesus macaques. <i>Npj Vaccines</i> , 2021, 6, 77.  | 2.9  | 11        |
| 566 | Cordycepin Inhibits Virus Replication in Dengue Virus-Infected Vero Cells. <i>Molecules</i> , 2021, 26, 3118.   | 1.7  | 22        |
| 567 | An affinity-matured human monoclonal antibody targeting fusion loop epitope of dengue virus with in vivo therapeutic potency. <i>Scientific Reports</i> , 2021, 11, 12987.  | 1.6  | 17        |
| 568 | Analysis of Neutralizing Antibodies as a Correlate of Instantaneous Risk of Hospitalized Dengue in Placebo Recipients of Dengue Vaccine Efficacy Trials. <i>Journal of Infectious Diseases</i> , 2022, 225, 332-340.  | 1.9  | 1         |
| 569 | Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Tdap Vaccine. <i>Pediatric Infectious Disease Journal</i> , 2021, 40, 856-863.  | 1.1  | 1         |
| 570 | Immunogenicity and safety of a tetravalent dengue vaccine and a bivalent HPV vaccine given concomitantly or sequentially in girls aged 9 to 14 years in Mexico. <i>Vaccine</i> , 2021, 39, 3388-3396.   | 1.7  | 3         |



| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 571 | Vaccines and Senior Travellers. <i>Frontiers in Aging</i> , 2021, 2, .  | 1.2 | 4         |
| 572 | Efficacy profile of the CYD-TDV dengue vaccine revealed by Bayesian survival analysis of individual-level phase III data. <i>ELife</i> , 2021, 10, .  | 2.8 | 5         |
| 573 | Knowledge gaps in the epidemiology of severe dengue impede vaccine evaluation. <i>Lancet Infectious Diseases</i> , The, 2022, 22, e42-e51.  | 4.6 | 20        |
| 574 | Dengue vaccine: an update. <i>Expert Review of Anti-Infective Therapy</i> , 2021, 19, 1495-1502.  | 2.0 | 22        |
| 575 | Morphological Diversity and Dynamics of Dengue Virus Affecting Antigenicity. <i>Viruses</i> , 2021, 13, 1446.   | 1.5 | 5         |
| 576 | Dengue vaccine breakthrough infections reveal properties of neutralizing antibodies linked to protection. <i>Journal of Clinical Investigation</i> , 2021, 131, .   | 3.9 | 22        |
| 577 | Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Quadrivalent Human Papillomavirus Vaccine in Boys and Girls 9â€“13 Years of Age in Malaysia. <i>Pediatric Infectious Disease Journal</i> , 2021, 40, 774-781. | 1.1 | 3         |
| 578 | Public trust and the COVIDâ€™19 vaccination campaign: lessons from the Philippines as it emerges from the Dengvaxia controversy. <i>International Journal of Health Planning and Management</i> , 2021, 36, 2048-2055.  | 0.7 | 26        |
| 579 | Estimating the reproduction number and designing the integrated strategies against dengue. <i>Results in Physics</i> , 2021, 27, 104473.  | 2.0 | 16        |
| 580 | Optimal Control of Dengue Transmission with Vaccination. <i>Mathematics</i> , 2021, 9, 1833.  | 1.1 | 6         |
| 581 | Evaluation of AT-752, a Double Prodrug of a Guanosine Nucleotide Analog with <i>In Vitro</i> and <i>In Vivo</i> Activity against Dengue and Other Flaviviruses. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, e0098821.                                      | 1.4 | 19        |
| 582 | Recent Insights Into the Molecular Mechanism of Toll-Like Receptor Response to Dengue Virus Infection. <i>Frontiers in Microbiology</i> , 2021, 12, 744233.   | 1.5 | 5         |
| 583 | Dengue Virus Serotype 1 Conformational Dynamics Confers Virus Strain-Dependent Patterns of Neutralization by Polyclonal Sera. <i>Journal of Virology</i> , 2021, 95, e0095621.  | 1.5 | 8         |
| 584 | Design of Monovalent and Chimeric Tetravalent Dengue Vaccine Using an Immunoinformatics Approach. <i>International Journal of Peptide Research and Therapeutics</i> , 2021, 27, 2607-2624.  | 0.9 | 7         |
| 585 | Competitive ELISA for a serologic test to detect dengue serotype-specific anti-NS1 IgGs using high-affinity UB-DNA aptamers. <i>Scientific Reports</i> , 2021, 11, 18000.   | 1.6 | 8         |
| 586 | Dengvaxia: the worldâ€™s first vaccine for prevention of secondary dengue. , 2021, 9, 251513552110158.  | 1.4 | 23        |
| 587 | Research of Dengue Fever Prediction in San Juan, Puerto Rico Based on a KNN Regression Model. <i>Lecture Notes in Computer Science</i> , 2017, , 146-153.   | 1.0 | 5         |
| 588 | Neutralizing and enhancing antibody responses to five genotypes of dengue virus type 1 (DENV-1) in DENV-1 patients. <i>Journal of General Virology</i> , 2017, 98, 166-172.   | 1.3 | 2         |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 589 | A lethal model of disseminated dengue virus type 1 infection in AG129 mice. <i>Journal of General Virology</i> , 2017, 98, 2507-2519.   | 1.3 | 26        |
| 590 | In-depth molecular analysis of a small cohort of human and <i>Aedes</i> mosquito (adults and larvae) samples from Kolkata revealed absence of Zika but high prevalence of dengue virus. <i>Journal of Medical Microbiology</i> , 2018, 67, 1109-1119. | 0.7 | 4         |
| 593 | Estimating the proportion of vaccine-induced hospitalized dengue cases among Dengvaxia vaccinees in the Philippines. <i>Wellcome Open Research</i> , 2019, 4, 165.  | 0.9 | 23        |
| 594 | Utility of a Dengue-Derived Monoclonal Antibody to Enhance Zika Infection In Vitro. <i>PLOS Currents</i> , 2016, 8, .   | 1.4 | 37        |
| 595 | The Dengue Vaccine Dilemma: Balancing the Individual and Population Risks and Benefits. <i>PLoS Medicine</i> , 2016, 13, e1002182.  | 3.9 | 30        |
| 596 | The Complexity of a Dengue Vaccine: A Review of the Human Antibody Response. <i>PLoS Neglected Tropical Diseases</i> , 2015, 9, e0003749.   | 1.3 | 86        |
| 597 | Production of Infectious Dengue Virus in <i>Aedes aegypti</i> Is Dependent on the Ubiquitin Proteasome Pathway. <i>PLoS Neglected Tropical Diseases</i> , 2015, 9, e0004227.  | 1.3 | 35        |
| 598 | <i>Cissampelos pareira</i> Linn: Natural Source of Potent Antiviral Activity against All Four Dengue Virus Serotypes. <i>PLoS Neglected Tropical Diseases</i> , 2015, 9, e0004255.  | 1.3 | 58        |
| 599 | Incomplete Protection against Dengue Virus Type 2 Re-infection in Peru. <i>PLoS Neglected Tropical Diseases</i> , 2016, 10, e0004398.   | 1.3 | 85        |
| 600 | Dengue Vaccine: Considerations before Rollout in Colombia. <i>PLoS Neglected Tropical Diseases</i> , 2016, 10, e0004653.  | 1.3 | 12        |
| 601 | Projected Impact of Dengue Vaccination in Yucatán, Mexico. <i>PLoS Neglected Tropical Diseases</i> , 2016, 10, e0004661.  | 1.3 | 44        |
| 602 | Predicting Dengue Fever Outbreaks in French Guiana Using Climate Indicators. <i>PLoS Neglected Tropical Diseases</i> , 2016, 10, e0004681.  | 1.3 | 43        |
| 603 | Wolbachia-Based Dengue Virus Inhibition Is Not Tissue-Specific in <i>Aedes aegypti</i> . <i>PLoS Neglected Tropical Diseases</i> , 2016, 10, e0005145.  | 1.3 | 39        |
| 604 | The Impact of the Newly Licensed Dengue Vaccine in Endemic Countries. <i>PLoS Neglected Tropical Diseases</i> , 2016, 10, e0005179.   | 1.3 | 146       |
| 605 | Socioeconomic and environmental determinants of dengue transmission in an urban setting: An ecological study in Nouméa, New Caledonia. <i>PLoS Neglected Tropical Diseases</i> , 2017, 11, e0005471.  | 1.3 | 66        |
| 606 | An economic evaluation of vector control in the age of a dengue vaccine. <i>PLoS Neglected Tropical Diseases</i> , 2017, 11, e0005785.  | 1.3 | 113       |
| 607 | Individual co-variation between viral RNA load and gene expression reveals novel host factors during early dengue virus infection of the <i>Aedes aegypti</i> midgut. <i>PLoS Neglected Tropical Diseases</i> , 2017, 11, e0006152.                   | 1.3 | 41        |
| 608 | Selection and Characterization of DNA Aptamers Targeting All Four Serotypes of Dengue Viruses. <i>PLoS ONE</i> , 2015, 10, e0131240.  | 1.1 | 39        |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 609 | Cost-effectiveness of dengue vaccination in Yucatán, Mexico using a dynamic dengue transmission model. PLoS ONE, 2017, 12, e0175020.  | 1.1 | 13        |
| 610 | Human dengue virus serotype 2 neutralizing antibodies target two distinct quaternary epitopes. PLoS Pathogens, 2018, 14, e1006934.  | 2.1 | 35        |
| 611 | Prevalence of dengue, Zika and chikungunya viruses in <i>Aedes (Stegomyia) aegypti</i> (Diptera: Culicidae) in a medium-sized city, Amazon, Brazil. Revista Do Instituto De Medicina Tropical De Sao Paulo, 2020, 62, e10.        | 0.5 | 16        |
| 612 | Arbovirus en Latinoamérica. Acta Pediatrica De Mexico, 2016, 37, 111.   | 0.2 | 15        |
| 613 | Análisis de la evidencia sobre eficacia y seguridad de la vacuna de dengue CYD-TDV y su potencial registro e implementación en el Programa de Vacunación Universal de México. Salud Publica De Mexico, 2016, 58, 71-83.           | 0.1 | 7         |
| 614 | Analysis of the evidence about the efficacy and safety of the CYD-TDV dengue vaccine and its potential licensing and implementation within the Mexican Universal Vaccination Program. Salud Publica De Mexico, 2016, 58, 71b-83b. | 0.1 | 5         |
| 615 | Dengue Fever: Historical Perspective and the Global Response. Journal of Infectious Diseases and Epidemiology, 2016, 2, .   | 0.1 | 5         |
| 616 | Improving the built environment in urban areas to control <i>Aedes aegypti</i> -borne diseases. Bulletin of the World Health Organization, 2017, 95, 607-608.   | 1.5 | 60        |
| 617 | Humanized Mice in Dengue Research: A Comparison with Other Mouse Models. Vaccines, 2020, 8, 39.   | 2.1 | 18        |
| 618 | The Molecular Interactions of ZIKV and DENV with the Type-I IFN Response. Vaccines, 2020, 8, 530.   | 2.1 | 22        |
| 619 | Biological view of vaccination described by mathematical modellings: from rubella to dengue vaccines. Mathematical Biosciences and Engineering, 2019, 16, 3195-3214.  | 1.0 | 19        |
| 620 | Controlling Dengue: Effectiveness of Biological Control and Vaccine in Reducing the Prevalence of Dengue Infection in Endemic Areas. Health, 2016, 08, 64-74.   | 0.1 | 4         |
| 621 | Phase 1 Randomized Study of a Tetravalent Dengue Purified Inactivated Vaccine in Healthy Adults in the United States. American Journal of Tropical Medicine and Hygiene, 2017, 96, 1325-1337.                                     | 0.6 | 50        |
| 622 | Cost-Effectiveness of Dengue Vaccination Programs in Brazil. American Journal of Tropical Medicine and Hygiene, 2017, 96, 1227-1234.  | 0.6 | 20        |
| 623 | Resource Use and Costs of Dengue: Analysis of Data from Phase III Efficacy Studies of a Tetravalent Dengue Vaccine. American Journal of Tropical Medicine and Hygiene, 2017, 97, 1898-1903.                                       | 0.6 | 5         |
| 624 | Dengue in Singapore from 2004 to 2016: Cyclical Epidemic Patterns Dominated by Serotypes 1 and 2. American Journal of Tropical Medicine and Hygiene, 2018, 99, 204-210.   | 0.6 | 69        |
| 625 | Bridging Efficacy of a Tetravalent Dengue Vaccine from Children/Adolescents to Adults in Highly Endemic Countries Based on Neutralizing Antibody Response. American Journal of Tropical Medicine and Hygiene, 2019, 101, 164-179. | 0.6 | 9         |
| 626 | No Evidence of Acute Dengue Virus Infections at a Rural Site in Western Kenya, 2011 and 2013. American Journal of Tropical Medicine and Hygiene, 2020, 103, 2054-2058.  | 0.6 | 2         |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 627 | Mathematical models of dengue fever epidemiology: multi-strain dynamics, immunological aspects associated to disease severity and vaccines. <i>Communication in Biomathematical Sciences</i> , 2017, 1, 1.             | 0.1 | 11        |
| 628 | Roadmap for the Introduction of a New Dengue Vaccine. , 0, , .   |     | 2         |
| 629 | The health perceptions, dengue knowledge and control willingness among Dai ethnic minority in Yunnan Province, China. <i>BMC Public Health</i> , 2021, 21, 1843.   | 1.2 | 6         |
| 630 | Local and Global Stability Analysis of Dengue Disease with Vaccination and Optimal Control. <i>Symmetry</i> , 2021, 13, 1917.  | 1.1 | 6         |
| 632 | Targets and strategies for vaccine development against dengue viruses. <i>Biomedicine and Pharmacotherapy</i> , 2021, 144, 112304.   | 2.5 | 15        |
| 634 | Evaluation of toxicity of Bordeaux Mixture in <i>Aedes aegypti</i> larvae (L. 1672) (Diptera: Culicidae) and Gram-negative and Gram-positive bacteria. <i>Journal of Mosquito Research</i> , 0, , .                    | 1.0 | 0         |
| 637 | V. Dengue Fever: Current Situation and Trends. <i>The Journal of the Japanese Society of Internal Medicine</i> , 2016, 105, 2140-2145.   | 0.0 | 0         |
| 638 | Arthropod-Borne Flaviviruses. , 0, , 1267-1311.  |     | 0         |
| 639 | The importance of B cells in the development of preventive and therapeutical approaches against Dengue, Zika and Chikungunya viral infections. <i>Brazilian Journal of Pharmaceutical Sciences</i> , 2016, 52, v-viii. | 1.2 | 0         |
| 640 | Caracterizaci3n de dengue y dengue severo en adultos hospitalizados en una instituci3n de Cartagena-Colombia.. <i>Revista Ciencias Biom3dicas (cartagena)</i> , 2016, 7, 212-222.                                      | 0.0 | 1         |
| 641 | Prospects for the Development of a Dengue Vaccine. <i>Journal of Vaccines and Immunology</i> , 2016, 2, 015-018.   | 0.3 | 0         |
| 643 | Challenges for Control of Arboviral Infections in South Asia. <i>Neglected Tropical Diseases</i> , 2017, , 387-404.  | 0.4 | 1         |
| 644 | Quick Evidence Synopsis. , 2017, , e38-e41.  |     | 0         |
| 646 | Modelo matem3tico que explica mejor la afectaci3n e identifica el patr3n relevante en la difusi3n para el dengue en la zona urbana del municipio de Neiva. <i>Entornos</i> , 2017, 30, 121-131.                        | 0.0 | 0         |
| 650 | Uso de pruebas NS1/IgM en ni±os con sospecha de dengue en un servicio de urgencias. <i>Revista M3dica Sanitas</i> , 2018, , .  | 0.1 | 1         |
| 653 | The Circumstance of Dengue Vaccine. <i>The Journal of the Japanese Society of Internal Medicine</i> , 2019, 108, 962-963.  | 0.0 | 0         |
| 655 | Mosquitoes (Culicidae). , 2020, , .  |     | 0         |
| 656 | Successive Immunization With Epitope-Decreasing Dengue Antigens Induced Conservative Anti-Dengue Immune Responses. <i>Frontiers in Immunology</i> , 2020, 11, 585133.  | 2.2 | 1         |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 657 | Discovery of Dengue Virus Inhibitors. <i>Current Medicinal Chemistry</i> , 2020, 27, 4945-5036.   | 1.2 | 3         |
| 658 | Immunobridging efficacy of a tetravalent dengue vaccine against dengue and against hospitalized dengue from children/adolescents to adults in highly endemic countries. <i>Transactions of the Royal Society of Tropical Medicine and Hygiene</i> , 2021, 115, 750-763. | 0.7 | 3         |
| 659 | Stimulation of B Cell Immunity in Flavivirus-Naïve Individuals by the Tetravalent Live Attenuated Dengue Vaccine TV003. <i>Cell Reports Medicine</i> , 2020, 1, 100155.   | 3.3 | 6         |
| 660 | Dengue Vaccines: An Update. <i>Pediatric Infectious Disease</i> , 2020, 2, 32-33.   | 0.0 | 0         |
| 661 | Stimulation of B Cell Immunity in Flavivirus-Naïve Individuals by the Tetravalent Live Attenuated Dengue Vaccine TV003. <i>SSRN Electronic Journal</i> , 0, , .   | 0.4 | 0         |
| 662 | Latent Infectious Capacities of Dengue Fever: Mathematical Modeling and Eco-Friendly Prevention Strategy. <i>Symmetry</i> , 2020, 12, 263.  | 1.1 | 0         |
| 664 | A method to estimate probability of disease and vaccine efficacy from clinical trial immunogenicity data. <i>Npj Vaccines</i> , 2021, 6, 133.   | 2.9 | 2         |
| 666 | Neutralizing Antibody Response and Efficacy of Novel Recombinant Tetravalent Dengue DNA Vaccine Comprising Envelope Domain III in Mice. <i>Iranian Journal of Medical Sciences</i> , 2017, 42, 152-160.   | 0.3 | 4         |
| 667 | Efficacy of Tetravalent Dengue Vaccine: A Systematic Review and Meta-Analysis. <i>Indian Journal of Community Medicine</i> , 2021, 46, 191-194.   | 0.2 | 0         |
| 668 | Predicting climate change and its impact on future occurrences of vector-borne diseases in West Bengal, India. <i>Environment, Development and Sustainability</i> , 0, , 1.   | 2.7 | 0         |
| 669 | Triphala in Traditional Ayurvedic Medicine Inhibits Dengue Virus Infection in Huh7 Hepatoma Cells. <i>Pharmaceuticals</i> , 2021, 14, 1236.   | 1.7 | 4         |
| 670 | Updates on Dengue Vaccine and Antiviral: Where Are We Heading?. <i>Molecules</i> , 2021, 26, 6768.  | 1.7 | 25        |
| 673 | A case-control study to determine the effectiveness of a tetravalent dengue vaccine in the state of Paraná, Brazil. <i>The Lancet Regional Health Americas</i> , 2022, 7, 100141.   | 1.5 | 2         |
| 674 | Pricing model for Dengue vaccine in Malaysia. <i>AIP Conference Proceedings</i> , 2021, , .   | 0.3 | 1         |
| 675 | Discovery of B-cell epitopes for development of dengue vaccines and antibody therapeutics. <i>Medical Microbiology and Immunology</i> , 2022, 211, 1-18.  | 2.6 | 3         |
| 676 | Brazilian Cerrado biome essential oils to control the arbovirus vectors <i>Aedes aegypti</i> and <i>Culex quinquefasciatus</i> . <i>Industrial Crops and Products</i> , 2022, 178, 114568.  | 2.5 | 5         |
| 678 | Current status and perspectives on vaccine development against dengue virus infection. <i>Journal of Microbiology</i> , 2022, 60, 247-254.  | 1.3 | 22        |
| 679 | Structures and Dynamics of Dengue Virus Nonstructural Membrane Proteins. <i>Membranes</i> , 2022, 12, 231.  | 1.4 | 9         |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 680 | High Throughput Screening Targeting the Dengue NS3-NS5 Interface Identifies Antivirals against Dengue, Zika and West Nile Viruses. <i>Cells</i> , 2022, 11, 730.   | 1.8 | 5         |
| 681 | Current Development and Challenges of Tetravalent Live-Attenuated Dengue Vaccines. <i>Frontiers in Immunology</i> , 2022, 13, 840104.  | 2.2 | 22        |
| 682 | Peculiarities of Zika Immunity and Vaccine Development: Lessons from Dengue and the Contribution from Controlled Human Infection Model. <i>Pathogens</i> , 2022, 11, 294.  | 1.2 | 5         |
| 683 | Mathematical models for dengue fever epidemiology: A 10-year systematic review. <i>Physics of Life Reviews</i> , 2022, 40, 65-92.  | 1.5 | 46        |
| 684 | Effect of a Vaccination against the Dengue Fever Epidemic in an Age Structure Population: From the Perspective of the Local and Global Stability Analysis. <i>Mathematics</i> , 2022, 10, 904.   | 1.1 | 2         |
| 685 | Antecedents customer decision to visit Yogyakarta as special regions in Indonesia. <i>Cogent Business and Management</i> , 2022, 9, .  | 1.3 | 3         |
| 686 | Immunogenicity and safety of booster CYD-TDV dengue vaccine after alternative primary vaccination schedules in healthy individuals aged 9â€“50 years: a randomised, controlled, phase 2, non-inferiority study. <i>Lancet Infectious Diseases</i> , The, 2022, , . | 4.6 | 2         |
| 687 | Structure-guided affinity maturation of a single-chain variable fragment antibody against the Fu-bc epitope of the dengue virus envelope protein. <i>Journal of Biological Chemistry</i> , 2022, 298, 101772.  | 1.6 | 6         |
| 688 | Prevention and control of dengue and chikungunya in Colombia: A cost-effectiveness analysis. <i>PLoS Neglected Tropical Diseases</i> , 2021, 15, e0010086.   | 1.3 | 3         |
| 708 | Generation of Mature DENVs via Genetic Modification and Directed Evolution. <i>MBio</i> , 2022, 13, e0038622.  | 1.8 | 11        |
| 709 | A crossâ€“sectional survey to evaluate prescribers' knowledge and understanding of safety messages following DengvaxiaÂ® product information update. <i>Pharmacoepidemiology and Drug Safety</i> , 2022, , .   | 0.9 | 1         |
| 710 | Accuracy and efficacy of pre-dengue vaccination screening for previous dengue infection with a new dengue rapid diagnostic test: a retrospective analysis of phase 3 efficacy trials. <i>Lancet Microbe</i> , The, 2022, 3, e427-e434.                             | 3.4 | 4         |
| 711 | Dengue: A Growing Problem With New Interventions. <i>Pediatrics</i> , 2022, 149, .   | 1.0 | 28        |
| 712 | Short communication: Feasibility of dengue vaccine to infect different human cell lines: An alternative potency test using HEK293T cells. <i>PLoS ONE</i> , 2022, 17, e0267653.  | 1.1 | 0         |
| 713 | Medicinal plants with anti-dengue and immunomodulatory activity. <i>Current Pharmaceutical Biotechnology</i> , 2022, 23, .   | 0.9 | 0         |
| 714 | Viral vector vaccines. <i>Current Opinion in Immunology</i> , 2022, 77, 102210.  | 2.4 | 28        |
| 715 | Performance Evaluation of a Dengue IgG Rapid Diagnostic Test Designed to Determine Dengue Serostatus as Part of Prevacination Screening. <i>Microbiology Spectrum</i> , 2022, 10, .  | 1.2 | 5         |
| 716 | Dengue Vaccines: An Update. <i>BioDrugs</i> , 2022, 36, 325-336.   | 2.2 | 34        |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 717 | Vaccine-induced antibodies to contemporary strains of dengue virus type 4 show a mechanistic correlate of protective immunity. <i>Cell Reports</i> , 2022, 39, 110930.   | 2.9 | 3         |
| 718 | Estimating the Time Reproduction Number in Kupang City Indonesia, 2016–2020, and Assessing the Effects of Vaccination and Different Wolbachia Strains on Dengue Transmission Dynamics. <i>Mathematics</i> , 2022, 10, 2075.            | 1.1 | 8         |
| 719 | Antibody Fc characteristics and effector functions correlate with protection from symptomatic dengue virus type 3 infection. <i>Science Translational Medicine</i> , 2022, 14, .   | 5.8 | 21        |
| 720 | Controlled Human Infection Models To Accelerate Vaccine Development. <i>Clinical Microbiology Reviews</i> , 2022, 35, .  | 5.7 | 12        |
| 721 | Zika virus-like particle vaccine fusion loop mutation increases production yield but fails to protect AG129 mice against Zika virus challenge. <i>PLoS Neglected Tropical Diseases</i> , 2022, 16, e0010588.                           | 1.3 | 2         |
| 722 | Mice immunized with trimethyl chitosan nanoparticles containing DENV-2 envelope domain III elicit neutralizing antibodies with undetectable antibody-dependent enhancement activity. <i>Journal of General Virology</i> , 2022, 103, . | 1.3 | 2         |
| 723 | A controlled effects approach to assessing immune correlates of protection. <i>Biostatistics</i> , 0, , .  | 0.9 | 7         |
| 724 | Sensitivity analysis for evaluating principal surrogate endpoints relaxing the equal early clinical risk assumption. <i>Annals of Applied Statistics</i> , 2022, 16, .   | 0.5 | 2         |
| 725 | Applications of self-replicating RNA. <i>International Review of Cell and Molecular Biology</i> , 2022, , .  | 1.6 | 3         |
| 726 | Reverse genetics in virology: A double edged sword. <i>Biosafety and Health</i> , 2022, 4, 303-313.  | 1.2 | 1         |
| 727 | World Dengue Day: A call for action. <i>PLoS Neglected Tropical Diseases</i> , 2022, 16, e0010586.   | 1.3 | 7         |
| 728 | Zika Virus Infection Alters Gene Expression and Poly-Adenylation Patterns in Placental Cells. <i>Pathogens</i> , 2022, 11, 936.  | 1.2 | 2         |
| 729 | Vaccine-associated enhanced disease in humans and animal models: Lessons and challenges for vaccine development. <i>Frontiers in Microbiology</i> , 0, 13, .   | 1.5 | 12        |
| 730 | Dengue virus NS4B protein as a target for developing antivirals. <i>Frontiers in Cellular and Infection Microbiology</i> , 0, 12, .  | 1.8 | 3         |
| 731 | Host immune response against DENV and ZIKV infections. <i>Frontiers in Cellular and Infection Microbiology</i> , 0, 12, .  | 1.8 | 6         |
| 732 | An optimal control model for COVID-19, zika, dengue, and chikungunya co-dynamics with reinfection. <i>Optimal Control Applications and Methods</i> , 2023, 44, 170-204.  | 1.3 | 19        |
| 733 | Neutralizing antibody correlates of sequence specific dengue disease in a tetravalent dengue vaccine efficacy trial in Asia. <i>Vaccine</i> , 2022, 40, 5912-5923.   | 1.7 | 0         |
| 734 | Efficacy of Dengue Vaccines in the Prevention of Severe Dengue in Children: A Systematic Review. <i>Cureus</i> , 2022, , .   | 0.2 | 0         |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 735 | Live-attenuated YF17D-vectored COVID-19 vaccine protects from lethal yellow fever virus infection in mouse and hamster models. <i>EBioMedicine</i> , 2022, 83, 104240.  | 2.7 | 5         |
| 736 | 16-jähriges Mädchen mit Fieber, Schmerzen und juckendem Ausschlag. , 2022, , 77-81.   |     | 0         |
| 737 | Zika Virus Vaccine: The Current State of Affairs and Challenges Posed by Antibody-Dependent Enhancement Reaction. <i>Viral Immunology</i> , 0, , .  | 0.6 | 3         |
| 738 | Evolution of inflammation and immunity in a dengue virus 1 human infection model. <i>Science Translational Medicine</i> , 2022, 14, .   | 5.8 | 13        |
| 739 | Dengue Epidemiology in Qatar from 2013â€“2021: A Retrospective Study. <i>Tropical Medicine and Infectious Disease</i> , 2022, 7, 329.   | 0.9 | 2         |
| 740 | Hemorrhagic fever viruses: Pathogenesis, therapeutics, and emerging and re-emerging potential. <i>Frontiers in Microbiology</i> , 0, 13, .  | 1.5 | 5         |
| 741 | To Vaccinate or Not to Vaccinateâ€”Reasons of Willingness and Reluctance of Students against SARS-CoV-2 Vaccinationâ€”An International Experience. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 14012.  | 1.2 | 7         |
| 743 | Antiviral peptides against dengue virus. , 2023, , 581-610.   |     | 0         |
| 744 | Preparedness for the Dengue Epidemic: Vaccine as a Viable Approach. <i>Vaccines</i> , 2022, 10, 1940.   | 2.1 | 8         |
| 745 | In the presence of non-neutralising maternally derived antibodies, intradermal and intramuscular vaccination with a modified live vaccine against porcine reproductive and respiratory syndrome virusÂ1 (PRRSV-1) induce similar levels of neutralising antibodies or interferon-gamma secreting cells. <i>Porcine Health Management</i> , 2022, 8, . | 0.9 | 3         |
| 746 | COVID-19 site readiness initiative: Building clinical trial capacity for vaccine efficacy trials in Latin America in response to the pandemic. <i>Vaccine: X</i> , 2022, 12, 100238.  | 0.9 | 0         |
| 747 | Biologics for dengue prevention: up-to-date. <i>Expert Opinion on Biological Therapy</i> , 0, , 1-15.   | 1.4 | 3         |
| 748 | Neutralization fingerprinting technology for characterizing polyclonal antibody responses to dengue vaccines. <i>Cell Reports</i> , 2022, 41, 111807.   | 2.9 | 0         |
| 749 | A Systematic Review of Mathematical Models of Dengue Transmission and Vector Control: 2010â€“2020. <i>Viruses</i> , 2023, 15, 254.  | 1.5 | 6         |
| 750 | Therapeutics for flaviviral infections. <i>Antiviral Research</i> , 2023, 210, 105517.  | 1.9 | 6         |
| 751 | Development and applications of mRNA treatment based on lipid nanoparticles. <i>Biotechnology Advances</i> , 2023, 65, 108130.  | 6.0 | 10        |
| 753 | The dengue virus 4 component of NIAIDâ€™s tetravalent TV003 vaccine drives its innate immune signature. <i>Experimental Biology and Medicine</i> , 2022, 247, 2201-2212.  | 1.1 | 2         |
| 754 | Dengue amid COVID-19 pandemic. <i>PLOS Global Public Health</i> , 2023, 3, e0001558.  | 0.5 | 4         |



| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 755 | Challenges on the development of a dengue vaccine: a comprehensive review of the state of the art. Journal of General Virology, 2023, 104, .  | 1.3 | 11        |
| 756 | Molecular Mechanisms of Antiviral Agents against Dengue Virus. Viruses, 2023, 15, 705.  | 1.5 | 11        |
| 757 | Application of estimand framework in ICH E9 (R1) to vaccine trials. Journal of Biopharmaceutical Statistics, 0, , 1-12.                       | 0.4 | 1         |
| 759 | Dengue: Update on Clinically Relevant Therapeutic Strategies and Vaccines. Current Treatment Options in Infectious Diseases, 2023, 15, 27-52. | 0.8 | 20        |
| 760 | A dengue vaccine whirlwind update. Therapeutic Advances in Infectious Disease, 2023, 10, 204993612311672.                                     | 1.1 | 3         |
| 772 | Genetic-Based Vaccine Vectors. , 2023, , 1374-1396.e11.   |     | 0         |
| 773 | Technologies for Making New Vaccines. , 2023, , 1350-1373.e9.   |     | 0         |
| 774 | Economic Analyses of Vaccine Policies. , 2023, , 1625-1639.e7.  |     | 0         |
| 775 | Vaccine Safety. , 2023, , 1679-1695.e10.  |     | 0         |
| 780 | Flaviviruses: Dengue. , 2023, , 1-65.   |     | 0         |